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   OPEN	  SOURCE	  BUSINESS	  MODELS	  AND	  SYNTHETIC	  BIOLOGY	  TEJ	  SINGH*	  	  ABSTRACT	  The	  software	  industry	  has	  successfully	  utilized	  open	  source	  busi-­‐ness	  models	  namely	  with	   software	  such	  as	  Android	  and	  Linux.	   	  Open	  source	  business	  models	  allow	  individuals	  to	  collaborate	  and	  share	   in-­‐formation	  without	   fear	   that	   the	   shared	   information	  will	   be	   commer-­‐cially	  misused.	   	   Given	   the	   similarities	   between	   software	   source	   code	  and	  genetic	  sequences,	  innovators	  in	  the	  field	  of	  synthetic	  biology	  feel	  that	  open	  source	  business	  models	  can	  help	  further	  innovation	  for	  syn-­‐thetic	   biology	   in	   a	   similar	   manner.	   	   However,	   when	   determining	  whether	  to	  join	  an	  open	  source	  project,	  practitioners	  must	  first	  identify	  if	  such	  a	  project	  will	  be	  beneficial	  to	  their	  goals.	  	  This	  Comment	  discuss	  benefits	   and	   risks	   associated	   with	   open	   source	   business	   models	   as	  applied	   to	   synthetic	   biology,	   as	  well	   as	   possible	   solutions	   to	   some	   of	  the	   risks	   identified.	   	   This	   Comment	   concludes	   with	   possible	   sugges-­‐tions	  to	  solve	  some	  of	  the	  issues	  associated	  with	  open	  source	  business	  models	  with	  the	  goal	  to	  further	  current	  open	  source	  initiatives.	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   I.	  INTRODUCTION	  Synthetic	  biology,	  “the	  synthesis	  of	  unnatural	  organic	  molecules	  that	  function	   in	   living	   systems,”	   is	   a	   rapidly	   emerging	   scientific	   discipline	   with	  numerous	  important	  industrial	  applications.1	  	  Synthetic	  biology	  applies	  to	  the	   fields	   of	  medicine,	   especially	   identifying	   and	   repairing	   genetically	   dam-­‐aged	   cells;	   agriculture,	   particularly	   genetically	  modified	  produce;	   and	   indus-­‐trial	   technology,	   namely	   biofuels.2	   	   Advances	   in	   synthetic	   biology	   have	   the	  potential	  to	  benefit	  humanity	  in	  a	  myriad	  of	  ways.3	  	  	   	  *	  J.D.	  candidate,	  University	  of	  San	  Diego	  School	  of	  Law.	  	  I	  thank	  Professor	  Ted	  Sichelman	  for	  his	  helpful	  comments.	  	   1.	   Steven	   A.	   Benner	   &	   A.	   Michael	   Sismour,	   Synthetic	   Biology,	   6	   NATURE	   REVIEWS	   GENETICS	  533,	  533	  (2005).	  	  	   2.	   Arti	   Rai	   &	   James	   Boyle,	   Synthetic	   Biology:	   Caught	   between	   Property	   Rights,	   the	   Public	  
Domain,	  and	  the	  Commons,	  5	  PLOS	  BIOLOGY	  389,	  389	  (2007).	  	  
	   3.	   Id.	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   457	  As	  with	  most	  other	  research	   fields,	   synthetic	  biology	  companies	   fre-­‐quently	  patent	  their	   inventions.4	   	  However,	  synthetic	  biology	  has	  been	  prob-­‐lematic.	   	   Specifically,	   courts	   have	   not	   clearly	   defined	   nonobviousness	   in	   the	  field	  of	  biosynthesis,5	  nor	  has	  the	  U.S.	  Patent	  &	  Trademark	  Office	  (USPTO)	  and	  the	   courts	   rigorously	   applied	   the	   enablement	   and	   written	   description	   doc-­‐trines	  to	  the	  field	  of	  synthetic	  biology.6	   	  These	  inadequacies	  have	  resulted	  in	  synthetic	  biology	  patents	  that	  are	  overly	  broad	  and	  often	  cover	  basic	  compo-­‐nents	  or	  parts	  of	  numerous	  synthetic	  biology	  products.7	  	  Such	  patents	  hinder	  new	  and	  important	  innovations	  by	  limiting	  the	  use	  of	  basic	  parts.8	  	  One	  possi-­‐ble	  solution	  to	  this	  problem	  could	  be	  the	  integration	  of	  open	  source	  business	  models	  to	  synthetic	  biology.9	  Software	   companies	   have	   successfully	   used	   open	   source	   business	  models;	   for	   example,	   the	   Linux	   operating	   system.10	   	   However,	   the	   synthetic	  biology	   field	  has	  only	   recently	   considered	  open	   source	   approaches.11	   	  Given	  the	  success	  of	  open	  source	  software,	  proponents	  of	  the	  business	  model	  analo-­‐gize	  synthetic	  biology	  to	  software	  and	  urge	  innovators	  to	  adapt	  a	  similar	  busi-­‐ness	  model.12	  	  Like	  computer	  engineers,	  synthetic	  biologists	  also	  use	  multiple	  parts	  when	  working	   on	   a	   new	  product.13	   	   “The	  hope	   is	   that	   an	   open-­‐source	  synthetic	   biology	   commons	   would	   encourage	   innovation	   in	   ways	   similar	   to	  the	   wildly	   successful	   open-­‐source	   software	   movement.”14	   	   However,	   open	  source	  business	  practices	  have	   “thus	   far	   failed	   to	  make	  much	   impact	   on	   the	  field	  of	  [synthetic]	  biology.”15	  	  	   4.	   Andrew	  W.	  Torrance,	  DNA	  Copyright,	  46	  VAL.	  U.	  L.	  REV.	  1,	  15–16	  (2011).	  	   5.	   Andrew	  W.	  Torrance	  &	  Linda	  J.	  Kahl,	  Bringing	  Standards	  to	  Life:	  Synthetic	  Biology	  Stand-­‐
ards	  and	  Intellectual	  Property,	  30	  SANTA	  CLARA	  HIGH	  TECH.	  L.J.	  199,	  203	  (2014);	  Brandon	  Smith,	  The	  
Patentability	  of	  Human	  Embryonic	  Stem	  Cells	  in	  Light	  of	  Myriad,	  96	  J.	  PAT.	  &	  TRADEMARK	  OFF.	  SOC’Y	  112,	   113	   (2014)	   (“[i]n	   the	   last	   five	   years,	   the	   Court	   has	   changed	   the	   landscape	   of	   patentable	  subject	  matter	  several	  times.”).	  	   6.	   Torrance	  &	  Kahl,	  supra	  note	  5,	  at	  203.	  	   7.	   Rai	  &	  Boyle,	   supra	  note	   2,	   at	   390–91;	   see	   also	  Smith,	   supra	  note	   5,	   at	   116	   (“[a]	   patent	  thicket	  would	  drastically	  decrease	  biotechnology	  companies’	  freedom	  to	  operate.”).	  	  
	   8.	   See	  Torrance	  &	  Kahl,	  supra	  note	  5,	  at	  203.	  “In	  theory,	  negative	  effects	  caused	  by	  patent	  rights	  covering	  commonly	  used	  components	  or	  methods	  in	  synthetic	  biology	  could	  be	  exacerbat-­‐ed	  if	  those	  patented	  components	  or	  methods	  were	  to	  be	  adopted	  as	  standards.”	  
	   9.	   See	  infra	  Part	  IV.B.	  	   10.	   Joachim	   Henkel	   &	   Stephen	   Maurer,	   The	   Economics	   of	   Synthetic	   Biology,	   MOLECULAR	  SYSTEMS	  BIOLOGY,	  June	  2007,	  at	  1;	  Jerry	  Hirsch	  &	  Tiffany	  Hsu,	  Elon	  Musk	  opens	  up	  Tesla	  patents	  to	  
everyone,	  LA	  TIMES	  (June	  12,	  2014,	  6:28	  PM),	  http://www.latimes.com/business/autos/la-­‐fi-­‐tesla-­‐open-­‐source-­‐20140613-­‐story.html#page=1.	   “The	   open-­‐source	   software	   movement	   has	   evolved	  over	   the	   last	   four	   decades,	   giving	   rise	   to	   systems	   such	   as	   the	   Linux	   operating	   system	   and	   the	  Mozilla	  Firefox	  Web	  browser,	  which	  can	  be	  freely	  customized	  and	  distributed.”	  	   11.	   Stephen	   Maurer,	   Before	   it’s	   Too	   Late,	   10	   EUR.	   MOLECULAR	   BIOLOGY	   ORG.	   REP.	   806,	   806	  (2009).	  
	   12.	   Id.	  	   13.	   A	  part,	  for	  the	  purposes	  of	  this	  paper	  and	  relative	  to	  synthetic	  biology,	  is	  essentially	  the	  genetic	  sequence	  or	  data	  that	  is	  used	  to	  create	  a	  basic	  component	  of	  an	  artificial	  biological	  system.	  	  	   14.	   Ethan	   R.	   Fitzpatrick,	   Open	   Source	   Synthetic	   Biology:	   Problems	   and	   Solutions,	   43	   SETON	  HALL	  L.	  REV.	  1363,	  1364	  (2013).	  	   15.	   Torrance,	  supra	  note	  4,	  at	  39.	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  This	   Comment	   analyzes	   the	   costs	   and	   benefits	   of	   the	   open	   source	  business	  model	  and	  its	  applicability	  to	  synthetic	  biology,	  alternative	  forms	  of	  legal	  protection	  for	  synthetic	  biology,	  and	  possible	  implementation	  strategies	  of	   an	  open	   source	  business	  model	   to	   synthetic	   biology.	   	   Benefits	   of	   an	  open	  source	   strategy	   include	   shared	   research	   and	   development	   costs,	   better	   and	  more	   reliable	   parts,	   better	   and	   cheaper	   final	   products,	   and	   a	   variety	   of	   per-­‐sonal	   incentives.16	   	   Some	   personal	   incentives	   regard	   one’s	   own	   reputation,	  impressing	   potential	   employers,	   and	   learning	   new	   skills.17	   	   However,	   some	  risks	  associated	  with	  open	  source	  business	  strategies	  include	  a	  lack	  of	  finan-­‐cial	  incentives,	  limited	  protections	  for	  sharing	  work,	  and	  limited	  incentives	  to	  entice	  other	  entities	  to	  participate	  in	  an	  open	  source	  project.18	  	  Furthermore,	  the	  benefits	  of	  a	  patent	  and	  the	  protections	  provided	  by	  patents	  still	  appeal	  to	  many	   companies,	   further	   preventing	   them	   from	   joining	   open	   source	   initia-­‐tives.19	  	  Of	  these	  risks,	  this	  Comment	  will	  argue	  that	  the	  greatest	  deterrent	  to	  open	  source	  projects	  is	  the	  lack	  of	  intellectual	  property	  protections	  for	  genetic	  sequences.20	   	  Thus,	  this	  Comment	  argues	  that	  more	  entities	  would	  be	  willing	  to	  participate	   in	  open	   source	  projects	   if	   copyright	   law	  extended	   to	   and	  pro-­‐tected	  genetic	  sequences.21	  	  As	  copyright	  protections	  are	  currently	  not	  availa-­‐ble	  to	  genetic	  sequences,	  copyright	  licenses	  may	  be	  a	  viable	  alternative	  to	  help	  protect	  shared	  information.22	  	  Further,	  this	  Comment	  discusses	  other	  possible	  remedies	  that	  will	  entice	  others	  to	  join	  open	  source	  initiatives.23	  	  For	  example,	  government	  incentives	  may	  help	  others	  join	  open	  source	  projects.24	  This	  comments	  proceeds	  as	  follows.	  	  Part	  II	  provides	  background	  in-­‐formation	  on	  synthetic	  biology,	  open	  source	  business	  models,	  and	  examples	  of	  current	   companies	   that	   have	   begun	   to	   implement	   an	   open	   source	   business	  model.	  	  Part	  III	  discusses	  current	  legal	  issues	  in	  the	  field	  synthetic	  biology	  for	  innovators.	  	  Part	  IV	  analyzes	  the	  application	  of	  an	  open	  source	  business	  model	  to	   synthetic	   biology	   including	   the	   benefits	   and	   the	   costs	   or	   risks	   of	   open	  source	  strategies.	  	  Part	  V	  presents	  possible	  solutions	  to	  the	  legal	  and	  non-­‐legal	  issues	   associated	  with	   synthetic	   biology.	   	   Part	   VI	   discusses	   actions	   that	   the	  government,	   congress,	  USPTO,	   and	   the	  Courts	   can	   take	   to	  help	   further	  open	  source	  initiatives,	  and	  the	  conclusion	  follows.	  II.	  WHAT	  IS	  SYNTHETIC	  BIOLOGY?	  The	  definition	   of	   synthetic	   biology	   varies	   depending	   on	   one’s	   technical	  	  
	   16.	   See	  infra	  Part	  IV.D.	  
	   17.	   See	  infra	  notes	  197–99	  and	  accompanying	  text.	  
	   18.	   See	  infra	  Part	  IV.E.	  
	   19.	   See	  infra	  Parts	  III.A.,	  IV.E.	  
	   20.	   See	  infra	  Part	  IV.F.	  
	   21.	   See	  infra	  Part	  V.A.	  
	   22.	   See	  infra	  Part	  V.B.	  
	   23.	   See	  infra	  Parts	  V.C.,	  VI.	  	  
	   24.	   See	  infra	  Part	  VI.	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  background.25	   	   Ethan	   Fitzpatrick	   summarized	   how	   different	   practitioners	  define	   “synthetic	   biology”	   in	   his	   article	  Open	   Source	   Synthetic	   Biology:	   Prob-­‐
lems	  and	  Solutions:	  [F]or	   the	   biologist,	   the	   term	  means	   ‘the	   ability	   to	   design	   and	   con-­‐struct	   synthetic	  biological	   systems	   [to]	  provide[]	   a	  direct	   and	   com-­‐pelling	   method	   for	   testing	   our	   current	   understanding.’	   	   For	   the	  chemist,	   ‘synthetic	  biology	   is	  an	  extension	  of	   synthetic	   chemistry[:]	  the	   ability	   to	   create	   novel	  molecules	   and	  molecular	   systems	   [to	   al-­‐low]	  the	  development	  of	  useful	  diagnostic	  assays	  and	  drugs,	  expan-­‐sion	   of	   genetically	   encoded	   functions,	   [and]	   study	   of	   the	   origins	   of	  life.	  .	  .’	  And	   finally,	   for	  engineers,	   synthetic	  biology	   is	  an	  attempt	   ‘to	  combine	  a	  broad	  expansion	  of	  biotechnology	  applications	  with	  .	  .	  .	  an	  emphasis	   on	   the	   development	   of	   foundational	   technologies	   that	  make	   the	  design	  and	  construction	  of	  engineered	  biological	   systems	  easier.’26	  	  Regardless	  of	  the	  technical	  background,	  synthetic	  biology	  essentially	  encompasses	   all	   aspects	   of	   research	   regarding	   genetic	  material.27	   	   Synthetic	  
organisms	  produced	  by	  synthetic	  biologists	  have	  medical	  applications	  and	  “a	  large	  variety	  of	  industrial”	  applications.28	  	  Synthetic	  biologists	  are	  also	  explor-­‐ing	   the	   “possibility	   of	   low-­‐cost	   production	   of	   ‘green’	   fuels	   such	   as	   cellulosic	  ethanol”	   as	   an	   alternative	   to	   current	   damaging	   fuels	   for	   both	   vehicles	   and	  electrical	  power.29	  To	   summarize	   genetics	   in	   a	   sentence,	   famous	   geneticist	   Francis	   Crick	  stated,	   “DNA	   makes	   RNA,	   RNA	   makes	   protein,	   and	   proteins	   make	   us.”30	  	  DNA—deoxyribonucleic	  acid—holds	  all	  of	  an	  organism’s	  genetic	  data.31	  	  DNA	  is	  composed	  of	  nucleotides—A,	  G,	  C,	  T.32	   	  Rearrangements	  of	   these	   four	  bio-­‐chemical	   compounds	   are	   responsible	   for	   all	   the	   complexity	   and	   diversity	   of	  living	   organisms	   on	   the	   planet.33	   	   Each	   cell	   in	   the	   human	   body	   contains	   an	  entire	  blueprint	  of	  highly	  condensed	  sequences	  of	  this	  genomic	  data.34	  	  Differ-­‐ential	  gene	  expression	  through	  transcription	  and	  translation	  allow	  the	  body	  to	  specify	  the	  construction	  of	  specific	  cells	  in	  specific	  locations,	  thus	  preventing	  mistakes	  like	  the	  development	  of	  cardiovascular	  cells	  in	  the	  digestive	  tract.35	  	  Although	  different	   cells	   in	   the	  body	  have	   the	   same	  DNA,	  different	   genes	   are	  	  	   25.	   Fitzpatrick,	  supra	  note	  14,	  at	  1367.	  
	   26.	   Id.	   (quoting	   Drew	   Endy,	   Foundations	   for	   Engineering	   Biology,	   438	   NATURE	   449,	   449	  (2005)).	  	   27.	   Fitzpatrick,	  supra	  note	  14,	  at	  1367.	  	   28.	   Sapna	   Kumar	  &	   Arti	   Rai,	   Synthetic	   Biology:	   The	   Intellectual	   Property	   Puzzle,	   85	   Tex.	   L.	  Rev.	  1745,	  1746	  (2007).	  
	   29.	   Id.	  	  	   30.	   Torrance,	  supra	  note	  4,	  at	  13.	  	   31.	   Benner	  &	  Sismour,	  supra	  note	  1,	  at	  534.	  	  
	   32.	   Id.	  	  
	   33.	   Id.	  	  
	   34.	   See	  CHRISTOPHER	  K.	  MATHEWS	  ET	  AL.,	  BIOCHEMISTRY,	  90–129	  (4th	  ed.	  2012).	  
	   35.	   Id.	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  activated	   or	   expressed	   in	   different	   cells,	   which	   is	   necessary	   for	   the	   cells	   to	  perform	  and	  function	  properly.36	  	  The	  process	  of	  transcription	  is	  the	  first	  step	  in	   the	   tangible	   realization	   of	   genetic	   information.37	   	   In	   this	   process,	   DNA	   is	  rewritten	  as	  complementary	  RNA	  strands.38	  RNA	  is	  composed	  of	  A,	  G,	  C	  nucleotides	  as	  well,	  but	  a	  U	  nucleotide	  is	  present	  rather	   than	  the	  T	  nucleotide.39	   	  The	   transcription	  process	  of	  DNA	  to	  RNA	   allows	   for	   highly	   diverse	   manipulations	   of	   our	   genetic	   information.40	  	  This	  process	  allows	  the	  genetic	  data	  stored	  on	  our	  forty-­‐six	  chromosomes	  to	  become	  even	  more	  diverse	  and	  expands	  its	  potential	  for	  unique	  arrangements	  of	  information.41	  	  Once	  the	  DNA	  is	  transcribed	  to	  RNA,	  the	  next	  step	  is	  transla-­‐tion	  of	  RNA	  to	  amino	  acids.	  	  There	  are	  twenty	  amino	  acids	  in	  the	  human	  body,	  and	   these	   biochemical	   compounds	   are	   the	   basic	   building	   blocks	   for	   all	   the	  proteins	   and	   enzymes	   in	   animals.42	   	   Thus,	   at	   this	   point,	   genetic	   information	  becomes	  a	  tangible	  protein	  or	  enzyme	  that	  performs	  a	  vital	  biochemical	  func-­‐tion	  in	  the	  body.43	  Researchers	  realize	  that	  manipulations	  of	  the	  basic	  underlying	  genet-­‐ic	   coding	   in	   an	   organism	   results	   in	   changes	   in	   the	   physical	   structures	   and	  functions	   of	   that	   organisms’	   cells.44	   	   As	   such,	   synthetic	   biologists	   use	   these	  nucleotides	   to	   create	  modified	   DNA	   strands	   that	   could	   have	  many	   different	  purposes.	   	  For	  example,	  synthetic	  biologist	  may	  create	  a	  genetically	  modified	  strand	  of	  carrot	  DNA	  that	  would	  make	  the	  carrot	  grow	  bigger	  and	  faster.45	  	  By	  manipulating	   the	   genetic	   code	   responsible	   for	   dictating	   the	   growth	   of	   the	  	  	   36.	   RUSSELL	  KORBKIN,	  STEM	  CELL	  CENTURY:	  LAW	  AND	  POLICY	  FOR	  A	  BREAKTHROUGH	  TECHNOLOGY	  7	  (2007).	   	  This	  information	  is	  extremely	  important	  for	  stem	  cell	  research.	   	  Id.	   	  Stem	  cells	  have	  the	  ability	   to	  differentiate	  between	  different	   types	  of	   cells	  based	  on	  gene	  expression.	   	   Id.	   	   Stem	  cell	  research	  is	  extremely	  important	  for	  advancements	  in	  the	  field	  of	  synthetic	  biology.	  	   37.	   CHRISTOPHER	  K.	  MATHEWS	  ET	  AL.,	  BIOCHEMISTRY,	  90–129	  (4th	  ed.	  2012).	  
	   38.	   Id.	  
	   39.	   Id.	  
	   40.	   Id.;	   Heidi	   Ledford,	   Bioengineers	   look	   Beyond	   Patents,	   499	   NATURE	   16,	   16	   (2013),	  http://www.nature.com/polopoly_fs/1.13320!/menu/main/topColumns/topLeftColumn/pdf/499016a.pdf.	  “Synthetic	  biologists	  aim	  to	  bring	  engineering	  principles	  to	  bear	  on	  genetic	  manipula-­‐tion,”	   and	   advancements	   in	   the	   field	   of	   synthetic	   biology	   are	   directly	   related	   to	   the	   ability	   to	  manipulate	  genetic	  data.);	  see	  also	  Mauricio	  Rojas	  et	  al.,	  Genetic	  engineering	  of	  proteins	  with	  cell	  
membrane	   permeability,	   16	   NATURE	   BIOTECHNOLOGY	   370,	   374	   (1998)	   (“[G]reat	   effort	   has	   been	  made	  to	  develop	  various	  methods	  of	  enhancing	  intracellular	  levels	  of	  specific	  proteins”	  for	  medi-­‐cal	  purposes	  and	  for	  a	  variety	  of	  researching	  purposes.	  	   41.	   CHRISTOPHER	  K.	  MATHEWS	  ET	  AL.,	  BIOCHEMISTRY,	  90–129	  (4th	  ed.	  2012).	  
	   42.	   Id.	  
	   43.	   Id.	  
	   44.	   See	  Sherret	  S.	  Chase,	  Anti-­‐Famine	  Strategy:	  Genetic	  Engineering	  for	  Food,	  25	  BULL.	  ATOMIC	  SCIENTISTS	   2,	   2–6	   (1969);	   Michael	   J.	   Mann	   et	   al.,	   Genetic	   engineering	   of	   vein	   grafts	   resistant	   to	  
atherosclerosis,	  92	  PROC.	  NATL.	  ACAD.	  SCI	  4502,	  4502	  (May	  1995).	  For	  example,	  “researchers	  have	  speculated	  that	  genetic	  engineering	  can	  improve	  the	  long-­‐term	  function	  of	  vascular	  grafts	  which	  are	  prone	  to	  atherosclerosis	  and	  occlusion.”	  	  Findings	  show	  that	  “an	  intraoperative	  gene	  therapy	  approach	  using	  antisense	  oligodeoxynucleotide	  blockage	  of	  medial	  smooth	  muscle	  cell	  prolifera-­‐tion	   can	   prevent	   the	   accelerated	   atherosclerosis	   that	   is	   responsible	   for	   autologous	   vein	   graft	  failure.”	  
	   45.	   See	  Chase,	  supra	  note	  44,	  at	  2–6.	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  carrot,	  scientists	  can	  essentially	  program	  their	  own	  coding	  that	  will	   increase	  the	   cellular	   rates	   of	   development	   in	   the	   carrot	   cells.46	   	   This	   type	   of	   genetic	  engineering	  has	  led	  to	  short-­‐stemmed	  wheat	  crops	  by	  engineering	  the	  plants	  with	  the	  Norin	  10	  gene,	  resulting	  in	  crops	  yielding	  more	  harvestable	  grain.47	  	  Similarly,	  attempts	  to	  maximize	  yield	  of	  crops	  have	  led	  to	  solving	  the	  problem	  of	   crop	   destruction	   from	   “disease	   and	   insects”	   and	   improving	   the	   “nutritive	  quality”	  of	  certain	  foods	  to	  incorporate	  necessary	  amino	  acids.48	   	  The	  advent	  of	   “artificial	   DNA	   cutters”	   and	   other	   designed	   molecular	   tools	   make	   these	  genetic	  engineer	  feats	  feasible.49	  Likewise,	   synthetic	   biologist	   identify	   genes	   that	   serve	   specific	   func-­‐tions	   to	   help	   fight	   diseases	   or	   that	   cause	   diseases.	   	   For	   example,	   synthetic	  biologist	   can	   identify	   the	   “gene	   products	   that	   enhance	   the	   ability	   of	  macro-­‐phages”	  that	  kill	  tubercle	  bacilli.50	  	  This	  information	  would	  be	  vital	  to	  finding	  and	  increasing	  resistance	  to	  M.	  tuberculosis.51	  	  Studying	  genetics	  and	  identify-­‐ing	  genetic	  sequences	  can	  be	  key	  in	  fighting	  many	  diseases.	  Scientists	   can	  write	   their	   own	   sequences	   of	   nucleotides	   and	   specify	  exactly	   which	   genes	   to	  manipulate	   within	   the	   coding	   of	   a	   particular	   organ-­‐ism.52	  	  Essentially,	  especially	  in	  the	  field	  of	  agriculture	  and	  medicine,	  synthetic	  biologists	  strive	  “to	  make	  genetic	  engineering	  faster	  and	  easier.”53	  	  The	  inven-­‐tion	  and	  application	  of	  next-­‐generation	  DNA	  and	  RNA	  sequencing	   to	  genetic	  engineering	   has	   increased	   the	   possibilities	   of	   creating	  more	   useful	   and	   spe-­‐cialized	  medical	  pharmaceuticals.54	   	  This	   technology	  has	  made	   it	  possible	   to	  sequence	  millions	  of	  DNA	  nucleotides	  accurately	  and	  efficiently	  in	  a	  matter	  of	  days.55	  	  Access	  to	  a	  set	  of	  previously	  modified	  genetic	  sequences	  in	  the	  public	  domain	  would	  allow	  synthetic	  biologists	   to	  work	  more	  efficiently	  and	  would	  give	  scientists	  further	  flexibility	  in	  future	  innovations.56	  
	  
	   46.	   Id.	  
	   47.	   Id.;	  Larry	  L.	  Green,	  Antibody	  engineering	  via	  genetic	  engineering	  of	  the	  mouse:	  XenoMouse	  
strains	  are	  a	  vehicle	   for	   the	   facile	  generation	  of	   therapeutic	  human	  monoclonal	  antibodies,	  231	   J.	  IMMUNOLOGICAL	  METHODS	  11,	  20	  (1999).	  Just	  as	  plants	  can	  be	  engineered,	  animals	  can	  be	  genetical-­‐ly	  modified	   and	   can	   be	   thus	   used	   to	   conduct	   genetic	   research	   for	  medical	   purposes.	   “By	   using	  XenoMouse	  animals	   and	  genetically	   engineering	   large	  portions	  of	   “thenative	  human	   Ig	   loci	   into	  the	  mouse	  germlin,”	  researchers	  were	  able	  to	  find	  that	  “with	  the	  human	  Ig	  transgenes	  functional-­‐ly	  replacing	  their	  murine	  counterparts,	  XenoMouse	  animals	  utilize	  the	  natural	  ability	  of	  the	  mu-­‐rine	  immune	  system	  to	  create	  high	  affinity	  human	  antibodies.”	  	  
	   48.	   See	  Chase,	  supra	  note	  44,	  at	  2–6.	  
	   49.	   Id.	  	   50.	   	  William	  W.	   Stead,	  MD,	  Genetics	   and	  Resistance	   to	   Tuberculosis,	   Could	   Resistance	   be	   en-­‐
hanced	  by	  genetic	  engineering?,	  116	  ANNALS	  OF	  INTERNAL	  MED.	  937,	  940	  (1992).	  	   51.	   	  Id.	  
	   52.	   See	  Chase,	  supra	  note	  44,	  at	  2–6.	  	   53.	   Fitzpatrick,	  supra	  note	  14,	  at	  1368.	  
	   54.	   See	  Chase,	  supra	  note	  44,	  at	  2–6.	  
	   55.	   Id.	  	  	   56.	   Maurer,	  supra	  note	  11,	  at	  806.	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  SYSTEM	  FOR	  SYNTHETIC	  BIOLOGY	  
A.	  Benefits	  of	  Patents	  Currently,	   the	   patent	   system	   is	   the	   “on	   the	   forefront	   of	   controver-­‐sies.”57	  	  Although	  this	  Comment	  focuses	  on	  the	  issues	  with	  the	  patent	  system	  in	  relation	   to	  synthetic	  biology,	   the	  patent	  system	  has	  many	  benefits.	   	  When	  an	  inventor	  creates	  a	  new	  technology,	  patent	  protection	  allows	  the	  inventor	  to	  share	  his	  invention	  to	  benefit	  society	  and	  allows	  the	  inventor	  to	  have	  property	  rights	  on	  his	  invention.58	  	  Patents	  create	  incentives	  for	  inventors	  to	  invent	  as	  patent	  law	  confers	  an	  “exclusive	  right	  to	  make,	  use,	  or	  sell	  the	  invention	  for	  a	  twenty-­‐year	  period.”59	  	  Patents	  are	  extremely	  important	  for	  pharmaceuticals;	  pharmaceuticals	  require	  regulatory	  approval	  before	  marketing	  can	  begin	  and	  patents	  prevent	  generic	  companies	  from	  entering	  the	  market.60	  	  Even	  though	  patents	   give	   inventors	   exclusive	   rights,	   “there	   is	   little	   or	   no	   reward	   to	   the	  inventor	   unless	   buyers”	   are	   interested	   in	   the	   innovation.61	   	   In	   essence,	   the	  patent	  system	  ensures	  that	  “incentives	  are	  directed	  towards	  generating	  prod-­‐ucts	  that	  people	  want”	  while	  protecting	  the	  innovator	  of	  that	  product.62	  
B.	  Issues	  With	  Patents	  The	  patent	  system	  is	  not	  without	  its	  faults.	  	  Innovators	  in	  the	  field	  of	  synthetic	  biology	  encounter	  a	  variety	  of	  legal	  roadblocks	  in	  their	  research	  due	  to	   patents.	   	   To	   begin,	   basic	   and	   obvious	   information	  may	   be	   covered	   under	  broad	  patents—which	  thereby	  hinders	  that	  information	  from	  being	  used	  for	  a	  different	  patent	  that	  might	  be	  more	  complex	  and	  useful.	  	  New	  technologies	  are	  “especially	   vulnerable	   to	   broad	   patents	   that	   suppress	   innovation.”63	   	   Fur-­‐thermore,	   basic	   manufacturing	   methods	   and	   process	   are	   susceptible	   to	   pa-­‐tents.	   	   When	   the	   patent	   covers	   basic	   methods	   of	   process,	   innovators	   must	  either	  pay	  licensing	  fees	  to	  use	  that	  method	  or	  figure	  out	  a	  new	  way	  to	  achieve	  the	  a	  similar	  result.64	   	  Both	  of	  these	  alternatives	  can	  be	  costly	  and	  inefficient	  for	  the	  innovator.	  	  	   57.	   Daniel	   Gifford,	   How	   do	   the	   Social	   Benefits	   and	   Costs	   of	   the	   Patent	   System	   Stack	   up	   in	  
Pharmaceuticals?,	  12	  J.	  INTELL.	  PROP.	  L.	  75,	  78	  (2004).	  	  
	   58.	   Id.	  at	  81.	  	  
	   59.	   Id.	  	  
	   60.	   Id.;	  Josh	  Bloom,	  Should	  Patents	  on	  Pharmaceuticals	  be	  Extended	  to	  Encourage	  Innovation?,	  WALL	   ST.	   J.	   1	   (2012),	  http://twileshare.com/uploads/_Should_Patents_on_Pharmaceuticals_Be_Extended_to_Encourage_Innovation.pdf	   ([p]atents	   are	   extremely	  beneficial	   to	   the	  pharmaceutical	   industry.	   In	   fact,	   the	  profits	   made	   during	   the	   scope	   of	   a	   patent	   funds	   “research	   that	   produces	   breakthrough	   treat-­‐ments.	   Many	   argue	   that	   patents	   should	   be	   extended	   for	   pharmaceutical	   companies	   because	  “[i]nnovation	  [d]emands	  [i]t”).	  	  	   61.	   Gifford,	  supra	  note	  57,	  at	  82.	  
	   62.	   Id.	  	  	   63.	   Fitzpatrick,	  supra	  note	  14,	  at	  1371.	  
	   64.	   Frequently	   Asked	   Questions,	   BIOBRICK	   FOUND.,	   https://biobricks.org/bpa/faq/#1	   (last	  visited	  Sept.	  9,	  2014).	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  Another	   issue	  with	  patents	   concerns	   foundational	  patents.	   	   Founda-­‐tional	   patents	   are	   “patents	  with	   broad	   claims	   that	   appeared	   important	   to	   a	  large	  percentage	  of	  work	  in	  the	  area.”65	  	  Foundational	  patents	  are	  problematic	  because	  foundational	  patents	  slow	  research	  and	  impede	  technology	  growth	  in	  the	  industry.66	  	  Because	  patents	  are	  granted	  subjectively	  and	  the	  Federal	  Cir-­‐cuit	  has	  a	  low	  nonobviousness	  threshold	  in	  the	  area	  of	  genetics,	  foundational	  patents	  are	   likely	   to	  be	  granted.67	   	  Currently,	   the	  Federal	  Circuit	  has	  a	  prob-­‐lematic	  way	   to	  determine	  obviousness.68	   	  Rather	   than	  applying	  what	   is	  non-­‐obvious	  to	  a	  practicing	  synthetic	  biologist,	  the	  courts	  focus	  on	  the	  “rules	  about	  nonobvious	   developed	   for	   chemical	   inventions	   in	   the	   mid-­‐twentieth	   centu-­‐ry.”69	   	   The	   United	   States	   Patent	   Office	   (USPTO)	   has	   also	   “failed	   to	   properly	  apply	   ‘nonobvious’	   in	   the	   fields	   of	   biotechnology.”70	   	   Practitioners	   fear	   that	  that	  same	  level	  of	  “nonobvious”	  will	  extend	  to	  synthetic	  biology,	  which	  would	  result	  in	  patents	  for	  foundational	  and	  basic	  parts.71	  	  In	  fact,	  broad	  patents	  are	  already	  present	  “in	   the	   field	  of	  synthetic	  biology.”72	   	  Researchers	  and	  practi-­‐tioners	  fear	  that	  foundational	  patents	  “will	  stifle	  the	  development	  of	  synthetic	  biology	   along	   with	   all	   of	   its	   potential	   benefits.”73	   	   In	   fact,	   such	   patents	   are	  already	  often	   “used	   to	  halt	   research,	   prevent	  medical	   testing,	   and	  keep	  vital	  information	  from”	  patients	  and	  doctors.74	  Even	  narrow	  patents	   can	  be	  problematic.	   	  Another	  major	   issue	  with	  the	  patent	  system	  is	  patent	  thickets.	  	  A	  patent	  thicket	  is	  an	  “overlapping	  set	  of	  patent	   rights	   requiring	   that	   those	   seeking	   to	   commercialize	   new	   technology	  obtain	  licenses	  from	  multiple	  patentees.”75	  	  Patent	  thickets	  occur	  when	  differ-­‐	  	   65.	   Kumar	   &	   Rai,	   supra	  note	   28,	   at	   1751;	  M.A.	   Heller	   &	   R.S.	   Eisenberg,	  Can	   Patents	   Deter	  
Innovation?The	   Anticommons	   in	   Biomedical	   Research,	   280	   SCIENCE	   698,	   698	   (1998),	  http://www.sciencemag.org/content/280/5364/698.full.pdf	   ([b]road	   patents	   that	   cover	   basic	  aspects	  of	  “nanotechnology	  —	  such	  as	  quantum	  dots,	  nanowires	  and	  fullerenes,	  carbon	  nanotubes	  and	  methods	   for	  making	   them	  —	  hamper	   conscientious	   innovators,	  who	  must	   spend	   time	   and	  money	  to	  acquire”	  licenses	  to	  utilize	  those	  parts	  to	  avoid	  lawsuits)	  	   66.	   Kumar	  &	  Rai,	  supra	  note	  28,	  at	  1753;	  but	  see	  M.	  A.	  Lemley,	  Patenting	  Nanotechnology,	  58	  STAN.	   L.	   REV.	   601,	   601	   (2005)	   (noting	   that	   “computing	   software	   grew	   up	   without	   overzealous	  patenting	  hindering	  innovation.”).	  	   67.	   Kumar	  &	  Rai,	  supra	  note	  28,	  at	  1753.	  
	   68.	   Id.	  at	  1749;	  see	  Smith,	  supra	  note	  5,	  at	  113	  (“[i]n	  the	  last	  five	  years,	  the	  Court	  has	  changed	  the	  landscape	  of	  patentable	  subject	  matter	  several	  times”).	  	   69.	   Kumar	  &	  Rai,	  supra	  note	  28,	  at	  1749.	  	   70.	   Rai	  &	  Boyle,	  supra	  note	  2,	  at	  390.	  
	   71.	   Id.	  
	   72.	   Id.	  	   73.	   Fitzpatrick,	  supra	  note	  14,	  at	  1371;	  see	  also	  Heller	  &	  Eisenberg,	  supra	  note	  65,	  at	  698.	  	   74.	   Torrance,	  supra	  note	  4,	  at	  17.	  	  	   75.	   Carl	   Shapiro,	  Navigating	   the	   Patent	   Thicket:	   Cross	   Licenses,	   Patent	   Pools,	   and	   Standard	  
Setting,	  1	  INNOVATION	  POLICY	  AND	  THE	  ECONOMY	  119,	  119	  (2001);	  Joshua	  M.	  Pearce,	  Make	  nanotech-­‐
nology	   research	   open-­‐source,	   491	   NATURE	   519,	   519	   (2012),	  http://www.nature.com/nature/journal/v491/n7425/full/491519a.html	   (“[a]ny	   innovator	  wishing	  to	  work	  on	  or	  sell	  products	  based	  on	  single-­‐walled	  carbon	  nanotubes	  in	  the	  United	  States	  must	   wade	   through	  more	   than	   1,600	   US	   patent”	   and	   then	   obtain	  multiple	   licenses	   to	   use	   any	  much	  of	  the	  basic	  and	  foundational	  information	  covered	  in	  those	  patents).	  	  
464	   CHICAGO-­‐KENT	  JOURNAL	  OF	  INTELLECTUAL	  PROPERTY	   [Vol	  14:2	  ent	   small	   bits	   of	   technology,	   such	   as	   computer	   data	   chips,	   are	   necessary	   to	  create	   a	   final	   product,	   such	   as	   a	   computer.	   	   Patent	   thickets	   pose	   issues	   for	  synthetic	  biologists,	  as	  with	  software	  engineers,	  because	  most	   final	  products	  utilize	  multiple	  parts,	  which	  may	  be	  patented.76	   	  For	  example,	  the	  number	  of	  patent	   applications	   for	   stem	   cells	   has	   been	   growing.77	   	   Scientists	   fear	   that	  patent	  thickets	  in	  stem	  cell	  technology	  would	  drastically	  decrease	  biotechnol-­‐ogy	  companies’	  ability	  to	  innovate.78	  Patents	  essentially	  provide	  a	  monopoly	  on	  the	   innovation	  that	  has	  a	  patent.79	   	  The	   innovation	   itself	  may	  be	   inferior,	  but	   it	   is	   the	  only	  product	  on	  the	  market	  for	  the	  duration	  of	  that	  monopoly.80	   	  Furthermore,	  patents	  cost	  a	  lot	   of	  money	   and	   time.81	   	   To	   get	   a	   patent,	   the	   innovator	  must	   pay	   attorney	  fees,	  wait	  for	  USPTO	  to	  approve	  the	  patent,	  and	  then	  pay	  maintenance	  fees	  on	  top	  of	  that	  to	  keep	  the	  patent.	  	  Simply	  put,	  “obtaining	  a	  patent	  is	  expensive—approximately	  $10,000	  in	  the	  US.”82	  Therefore,	   there	  are	  many	  reasons	  why	  a	  company,	  particularly	  a	  small	  business	   or	   academic	   facility,	   would	   look	   at	   the	   patent	   system	   unfavorably.	  	  Patents	  often	  cover	  basic	  information,	  basic	  methods	  or	  processes,	  fundamen-­‐tal	  technologies,	  and	  patents	  are	  extremely	  expensive.	   	  However,	  besides	  pa-­‐tents,	  innovators	  cannot	  seek	  any	  other	  types	  of	  intellectual	  property	  rights.83	  	  The	  biggest	   legal	  hurdle	   that	   synthetic	  biologist	   face	  but	   software	  engineers	  do	  not	  “is	  that	  gene	  data—unlike	  software—cannot	  be	  copyrighted.”84	  
C.	  Issues	  from	  recent	  Supreme	  Court	  Cases	  Case	   law	   concerning	   patentability	   of	   synthetic	   biology	   is	   murky	   at	  best.85	   	  The	  courts	  and	  the	  USPTO	  have	  yet	  to	  define	  nonobvious	  and	  proper	  patentable	  subject	  matter	  for	  synthetic	  biology	  related	  patents.86	  	  However,	  in	  
Association	  for	  Molecular	  Pathology	  v.	  Myriad	  Genetics,	  Inc.,	  the	  Court	  held	  that	  	  	   76.	   Kumar	  &	  Rai,	  supra	  note	  28,	  at	  1757;	  see	  Pearce,	  supra	  note	  76,	  at	  519	  (patent	  thickets	  hinder	  nanotechnology.	  “Excessive	  patenting	  is	  increasing	  costs,	  slowing	  technical	  development[,]	  and	   removing	   from	   the	   public	   domain	   fundamental	   knowledge	   about	   the	   understanding	   and	  control	  of	  matter	  on	  the	  atomic	  or	  molecular	  scale.”).	  	   77.	   	  Smith,	  supra	  note	  5,	  at	  116.	  	   78.	   	  Id.	  	   79.	   Henkel	  &	  Maurer,	  supra	  note	  10,	  at	  2.	  	  
	   80.	   Id.	  
	   81.	   Frequently	  Asked	  Questions,	  supra	  note	  64.	  	  	   82.	   Maurer,	  supra	  note	  11,	  at	  808;	  Smith,	  supra	  note	  5,	  at	  113	  (“in	  1874,	  the	  Court	  held	  that	  purified	  paper	  pulp	  cellulose	  was	  not	  patentable	  subject	  matter,	  yet	  the	  Court	  ruled	  in	  1980	  that	  a	  genetically	  modified	  bacterium	  was	  patentable	  subject	  matter.);	  see	  American	  Wood-­‐Paper	  Co.	  v.	  Fibre	  Disintegrating	  Co.,	  90	  U.S.	  566,	  594-­‐607	  (1874);	  see	  Diamond	  v.	  Chakrabarty,	  447	  U.S.	  303,	  309-­‐10	  (1980).	  	   83.	   Maurer,	   supra	  note	   11,	   at	   808;	   Smith,	   supra	  note	   5,	   at	   113	   (“in	   the	   last	   five	   years,	   the	  Court	  has	  changed	  the	  landscape	  of	  patentable	  subject	  matter	  several	  times.”).	  	   84.	   Maurer,	  supra	  note	  11,	  at	  808.	  	  	   85.	   Rai	  &	  Boyle,	  supra	  note	  2,	  at	  390.	  
	   86.	   Id.	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  natural	  DNA	  is	  not	  patentable.87	   	   In	  Myriad,	  Myriad	  Genetics,	   Inc.	  discovered	  the	   location	   and	   sequence	  of	   two	  naturally	   occurring	  human	  genes—BRCA1	  and	  BRCA2.88	  	  These	  genes	  are	  associated	  with	  breast	  and	  ovarian	  cancer,	  and	  mutations	   in	   these	   genes	   can	   help	   identify	   individuals	   more	   likely	   to	   have	  such	   cancers.89	   	   After	   discovering	   the	   location	   and	   sequences	   of	   the	   genes,	  Myriad	   sought	   and	   obtained	   a	   number	   of	   patents	  with	  multiple	   claims.90	   	   If	  valid,	  the	  patents	  would	  give	  Myriad	  “exclusive	  right	  to	  isolate”	  and	  create	  an	  individual’s	   BRCA1	   and	   BRCA2	   genes.91	   	   The	   University	   of	   Pennsylvania’s	  Genetic	   Diagnostic	   Laboratory	   (GDL)	   and	   Dr.	   Ostrer	   also	   conducted	   similar	  genetic	  testing	  services	  to	  women.92	  	  Myraid	  responded	  with	  letters	  asserting	  patent	  infringement	  forcing	  GDL	  and	  Dr.	  Ostrer	  to	  cease	  sequencing.93	  Some	  years	  later,	  Dr.	  Ostrer	  and	  others	  filed	  a	  lawsuit	  seeking	  a	  dec-­‐laration	  that	  Myriad’s	  patents	  were	  invalid.94	  	  Although	  the	  District	  Court	  held	  that	  the	  claims	  were	  invalid	  because	  the	  patented	  genes	  were	  naturally	  occur-­‐ring,	  the	  Federal	  Circuit	  reversed	  and	  held	  that	  the	  isolated	  genetic	  materials	  were	  patent	  eligible	  under	  35	  U.S.C.	  §	  101.95	  	  The	  issue	  in	  dispute	  was	  wheth-­‐er	  “separating	  a	  specific	  gene	  or	  sequence	  of	  nucleotides	  from	  the	  rest	  of	  the	  chromosome”	  was	  enough	  to	  grant	  the	  first	  individual	  to	  isolate	  that	  sequence	  a	  patent.96	   	  The	  Supreme	  Court	  granted	  certiorari	  and	  held	  that	  patents	  can-­‐not	  claim	  naturally	  occurring	  phenomena.97	  In	   their	   decision,	   the	   Court	   relied	   on	  Diamond	   v	   Chakrabarty.98	   	   In	  
Chakrabarty,	   scientists	  modified	  bacterium	  by	  adding	  plasmids	   to	   the	  bacte-­‐rium—which	  enabled	  it	  to	  break	  down	  crude	  oil.99	  	  The	  Court	  in	  Chakrabarty	  held	  that	  the	  modified	  bacterium	  was	  patentable	  because	  it	  was	  not	  a	  “natural	  phenomenon”	   but	   instead	   “a	   product	   of	   human	   ingenuity	  with	   a	   distinctive	  name,	   character	   [and]	   use.”100	   	   By	   contrast,	   the	   BRCA	   genes	   discovered	   in	  
Myriad	   were	   naturally	   occurring,	   and	  Myriad	   did	   not	   add	   anything	   to	   those	  genes.101	   	   The	   Court	   in	  Myriad	   held	   that	   “separating	   [a]	   gene	   from	   its	   sur-­‐	  	   87.	   133	  S.	  Ct.	  2107,	  2117	  (2013).	  
	   88.	   Id.	  at	  2112.	  
	   89.	   Id.	  	  
	   90.	   Id.	  at	  2113.	  
	   91.	   Id.	  	  
	   92.	   Id.	  at	  2114.	  	  
	   93.	   Id.	  	  
	   94.	   Id.	  	  
	   95.	   Id.;	   35	   U.S.C.	   §	   101	   (2014)	   provides	   that	   “Whoever	   invents	   or	   discovers	   any	   new	   and	  useful	  process,	  machine,	  manufacture,	  or	  composition	  of	  matter,	  or	  any	  new	  and	  useful	  improve-­‐ment	   thereof,	  may	   obtain	   a	   patent	   therefor,	   subject	   to	   the	   conditions	   and	   requirements	   of	   this	  title.”	  
	   96.	   Ass’n	  for	  Molecular	  Pathology,	  133	  S.	  Ct.	  at	  2114.	  
	   97.	   Id.	  	  
	   98.	   Id.	  at	  2116.	  	   99.	   Diamond	  v.	  Chakrabarty,	  447	  U.S.	  303,	  305	  (1980).	  
	   100.	   Id.	  at	  309–10	  (internal	  quotations	  omitted).	  	  
	   101.	   Ass’n	  for	  Molecular	  Pathology,	  133	  S.	  Ct.	  at	  2117.	  
466	   CHICAGO-­‐KENT	  JOURNAL	  OF	  INTELLECTUAL	  PROPERTY	   [Vol	  14:2	  rounding	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  material	  is	  not	  an	  act	  of	  invention.”102	  One	  of	  Myriad’s	  arguments	  exemplifies	  the	  problem	  with	  the	  USPTO;	  Myriad	   argued	   that	   its	   patent	   should	   not	   be	   invalidated	   because	   the	  USPTO	  had	  a	  history	  of	  awarding	  gene	  patents.103	   	  Myriad’s	  argument	  illustrates	  the	  contention	  that	   the	  USPTO	  does	  not	  have	  specific	  guidelines	   for	  determining	  patentability,	  and	  the	  Courts	  have	  yet	  to	  resolve	  this	   issue.	   	  Although	  Myriad	  resolved	   some	   issues	   of	   what	   is	   patent-­‐eligible,	   neither	   congress	   nor	   the	  USPTO	  have	  defined	  what	  is	  nonobvious.	  The	   Court	   in	  Myriad	   further	   held	   that	   the	   ruling	   did	   not	   extend	   to	  methods	   or	   new	   applications	   involving	   knowledge	   of	   the	   BRCA	   genes.104	  	  Furthermore,	  the	  Court	  added	  that	  modified	  DNA	  is	  still	  patentable.105	  	  Myriad	  by	  far	  has	  been	  the	  most	  significant	  decision	  in	  the	  field	  of	  synthetic	  biology.	  	  Before	  the	  ruling,	  patent	  prosecutors	  would	  routinely	  file	  patents	  after	  isolat-­‐ing	  genetic	  sequences.106	   	  The	  decision,	  however,	  still	  allows	  synthetic	  biolo-­‐gists	   to	   seek	   patents	   on	   modified	   genetic	   data.	   	   Myriad	   merely	   excludes	  scientists	  and	  patent	  prosecutors	  from	  seeking	  patents	  on	  genetic	  data	  that	  is	  present	  in	  nature,	  even	  if	  it	  is	  extremely	  difficult	  to	  isolate.107	  Case	  law	  regarding	  intellectual	  property	  protections	  for	  software	  has	  been	  similarly	  unclear.	  	  In	  June	  2014,	  the	  United	  States	  Supreme	  Court	  in	  Alice	  
Corp.	  held	  that	  otherwise	  patent-­‐illegible	  abstract	  ideas	  cannot	  be	  patented	  if	  the	  claim	  merely	   tries	   to	  apply	  that	   idea	  with	  a	  computer.108	   	  The	  Court	  dis-­‐cussed	  Myriad	  Genetics	  and	  Mayo	  Collaborative	  Services	  v.	  Prometheus	  Labora-­‐
tories,	   Inc.	   in	   its	   ruling.	   	   The	   analysis	   of	   these	   cases	   is	   of	   particular	   interest	  given	   that	   both	   cases	   concern	   synthetic	   biology	   while	   Alice	   Corp	   concerns	  software.	  In	  Mayo,	   the	  claims	  concerned	  the	  processes	  that	  helped	  doctors	  de-­‐termine	   the	   proper	   dosage	   of	   a	   thiopurine	   drug	   used	   to	   treat	   patients	  with	  autoimmune	  diseases.109	  	  The	  claims	  essentially	  applied	  natural	  laws	  describ-­‐ing	   the	   relationship	  between	   the	   concentration	  of	   certain	   tiopurine	  metabo-­‐lites	  in	  the	  blood	  and	  the	  effects	  the	  drug	  would	  have	  on	  the	  person	  based	  on	  those	  concentrations.110	  	  The	  issue	  was	  whether	  the	  claimed	  processes	  trans-­‐formed	   “unpatentable	   natural	   laws	   into	   patent	   eligible	   applications	   of	   those	  laws.”111	   	   The	   Court	   held	   that	   those	   claims	   did	   not	   and	   thus	   the	   processes	  	  
	   102.	   Id.	  	  
	   103.	   Id.	  at	  2118;	  see	  also	  J.E.M	  Ag	  Supply,	  Inc.	  v.	  Pioneer	  Hi-­‐Bred	  Int’l,	  Inc.,	  534	  U.S.	  124,	  125	  (2001).	  	  
	   104.	   Ass’n	  for	  Molecular	  Pathology,	  133	  S.	  Ct.	  at	  2118.	  
	   105.	   Id.	  	  
	   106.	   See	  Torrance,	   supra	  note	   4,	   at	   17	   (“approximately	   20%	  of	   known	   genes	   in	   the	   human	  genome	  have	   been	   claimed	   in	   patents	   issued	   by	   the”	  USPTO	  based	   on	   information	   available	   in	  2005).	  
	   107.	   Ass’n	  for	  Molecular	  Pathology,	  133	  S.	  Ct.	  at	  2118.	  	   108.	   Alice	  Corp.	  Pty.	  Ltd.	  v.	  CLS	  Bank	  Int’l,	  134	  S.	  Ct.	  2347,	  2349	  (2014).	  	  	   109.	   Mayo	  Collaborative	  Serv.	  v.	  Prometheus	  Labs,	  Inc.,	  132	  S.	  Ct.	  1289,	  1294	  (2012).	  	  
	   110.	   Id.	  	  
	   111.	   Id.	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  were	  not	  patentable.112	  The	   Court	   in	  Alice	   Corp	   applied	   the	   two-­‐part	   test	   from	  Mayo	   to	   the	  software	   claims	   at	   issue;	   the	   Court	   first	   examined	   the	   claim	   to	   determine	  whether	   the	   claims	   at	   issue	   regarded	   a	   patent-­‐ineligible	   concept	   and	   then	  whether	   it	   contained	   an	   “inventive	   concept”	   sufficient	   to	   “transform”	   the	  claimed	  abstract	  idea	  into	  a	  patent-­‐eligible	  application.113	  	  The	  Court	  held	  that	  the	   method	   claims—which	   simply	   required	   generic	   computer	   implementa-­‐tion—failed	  to	  transform	  the	  abstract	  idea	  of	  intermediated	  settlement	  into	  a	  patent	  eligible	  invention.114	  Given	  the	  similarities	  between	  software	  and	  synthetic	  biology,	  the	  courts	  may	  soon	  expand	  software	  law	  to	  the	  realm	  of	  synthetic	  biology.	  	  The	  analysis	  used	  in	  the	  case	  law	  discussed	  illustrates	  that	  the	  Court	  was	  willing	  to	  extend	  its	  analysis	  for	  patent	  eligibility	  from	  one	  technical	  field	  to	  another.	  	  However,	  another	  issue	  is	  what	  the	  Court	  will	  find	  to	  be	  patent	  ineligible	  next.115	  	  Based	  on	   the	  uncertainty	   and	   limits	   on	  patentability,	   companies	  may	   soon	   explore	  open	   source	   business	   models	   for	   their	   companies	   to	   avoid	   any	   legal	   issues	  created	  by	  the	  recent	  case	  law.116	  IV.	  OPEN	  SOURCE	  BUSINESS	  MODEL	  FOR	  SYNTHETIC	  BIOLOGY	  Although	   an	   open	   source	   business	  model	   for	   synthetic	   biology	  may	  work,	   there	   is	   no	   guarantee.117	   	   Compared	   to	   the	   software	   industry,	   biology	  research	   has	   not	   exploited	   the	   power	   of	   shared,	   standardized	   components,	  but	   that	   is	   changing.118	   	   Open	   source	   business	  models	   have	   both	   costs	   and	  benefits—which	  must	  be	  thoroughly	  analyzed	  before	  concluding	  that	  synthet-­‐ic	  biologists	  should	  immediately	  implement	  open	  source	  business	  strategies.	  
A.	  What	  is	  Open	  Source?	  The	   term	   “open	   source”	   refers	   to	   information	   that	   “can	  be	  modified	  because	   its	   design	   is	   publicly	   accessible.”119	   	   Open	   source	  models	   are	  most	  commonly	  associated	  with	  software.120	  	  When	  a	  software	  producer	  decides	  to	  implement	   an	   open	   source	   business	   model,	   they	   “make	   their	   source	   code	  	  
	   112.	   Id.	  	  
	   113.	   Alice	  Corp.,	  134	  S.	  Ct.	  at	  2355.	  
	   114.	   Id.	  at	  2357.	  
	   115.	   See	  Torrance	  &	  Kahl,	   supra	  note	  5,	  at	  203	   (“[i]n	  practice,	   the	  past	   few	  years	  have	  seen	  tremendous	  flux	  in	  how	  courts	  interpret	  the	  patent-­‐eligibility	  of	  both	  methods,	  such	  as	  diagnostic	  tests,	  and	  components,	  such	  as	  isolated	  DNA	  molecules,	  essential	  to	  synthetic	  biology.”).	  
	   116.	   Id.	  	  
	   117.	   See	  Stephen	  M.	  Maurer	  et	  al.,	  Finding	  Cures	   for	  Tropical	  Diseases:	   Is	  Open	  Source	  an	  An-­‐
swer?,	  6	  MINN.	  J.L.	  SCI.	  &	  TECH.	  169,	  172	  (2004).	  	   118.	   Henkel	  &	  Maurer,	  supra	  note	  10,	  at	  1.	  
	   119.	   See	   What	   is	   Open	   Source?,	   OPENSOURCE.COM,	   http://opensource.com/resources/what-­‐open-­‐source	  (last	  visited	  Mar.	  24,	  2015).).	  	  
	   120.	   Id.	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  freely	  available	  for	  improvement,	  modification,	  and	  redistribution.”121	  	  These	  producers	   believe	   that	   profits	   realized	   through	   “software	   services	   and	   sup-­‐port	  (rather	  than	  for	  the	  software	  itself)	  is	  more	  lucrative.”122	  Open	  source	  software	  has	  many	  advantages.	   	  First,	   “[o]pen	  source	  soft-­‐ware	  comes	  free	  of	  license	  fees.”123	  	  In	  other	  words,	  this	  means	  that	  the	  buyer	  pays	   less	   for	   the	   software,	   and	   sometimes	   the	   software	   is	   available	   at	   no	  cost.124	   	  Second,	  the	  software	  can	  be	  easily	  modified	  to	  meet	  “the	  customer’s	  needs.”125	  	  Because	  the	  software	  code	  is	  available,	  anyone	  can	  modify	  the	  code	  to	  meet	  a	  specific	  consumer	  need.126	   	  Accordingly,	  users	  can	  quickly	   identify	  and	  fix	  bugs	  in	  the	  software	  or	  build	  enhancements	  for	  the	  software	  based	  on	  consumer	  needs.127	  	  Proprietary	  software,	  on	  the	  other	  hand,	  is	  improved	  and	  fixed	  depending	  on	  the	  “motivation	  and	  resources	  of	  the	  software	  developer”	  rather	  than	  by	  need	  of	  the	  user.128	  	  Third,	  the	  software	  has	  a	  “worldwide	  audi-­‐ence”	  due	  to	  its	  low	  costs.129	  	  In	  other	  words,	  because	  there	  are	  minimal	  fees	  to	   get	   the	   software,	   everyone	   around	   the	  world	   theoretically	   can	   access	   the	  software	  regardless	  of	  their	  economic	  status.130	  However,	  open	  source	  software	  also	  has	  its	  disadvantages.	  	  First,	  be-­‐cause	   the	  software	   is	  open	  source	  and	   the	  source	  code	   is	  available	   to	  every-­‐one,	   any	   software	   “products	   derived	   from	   the	   source	   code”	   must	   also	   be	  available	   freely.131	   	   Thus,	   software	   producers	   are	   “constrained	   to	   give	   away	  the	  fruits	  of	  their	  labor.”132	  	  Second,	  due	  to	  a	  lack	  of	  funding,	  open	  source	  pro-­‐	  	   121.	   Rai	  &	  Boyle,	  supra	  note	  2,	  at	  391;	  see	  also	  Jason	  C.	  Goldwater	  et	  al.,	  The	  Use	  of	  Open	  Source	  
Electronic	  Health	  Records	  within	  the	  Federal	  Safety	  Net,	  21	  J.	  AM.	  MED.	  INFO.	  ASS’N	  280,	  280	  (2014)	  (“[b]ecause	  the	  source	  code	  is	  freely	  available	  to	  all	  potential	  users,	  open	  source	  software	  devel-­‐opment	  is	  more	  flexible	  and	  transparent	  than	  other	  processes	  and,	  therefore,	  encourages	  a	  prac-­‐tice	  of	  collaboration	  among	  developers	  and	  users	  of	  the	  software.”).	  
	   122.	   See	  What	  is	  Open	  Source?,	  supra	  note	  119.	  	   123.	   Bennett	  M.	   Sigmond,	  Free/Open	   Source	   Software	   Licensing–Too	   Big	   to	   Ignore,	   34	   COLO.	  LAW.	  89,	  90	  (2005).	  	  
	   124.	   Id.	  	  
	   125.	   Id.	  	  
	   126.	   See	  Goldwater	   et	   al.,	   supra	   note	   121,	   at	   280	   (“[t]he	   open	   source	   community	   promotes	  sharing,	  enhancing	  and	  adding	  applications	   to	   the	  base	  source	  code,	  and	  provides	  an	  avenue	   to	  release	  modified	  versions	  of	  the	  application	  for	  the	  benefit	  of	  the	  user	  community	  as	  a	  whole.”).	  
	   127.	   See	   Sigmond,	   supra	   note	   123,	   at	   90;	   Quentin	   Hardy,	  Open	   source	   and	   the	   Challenge	   of	  
Making	  Money,	  BITS	   (July	  23,	  2014,	  2:28	  PM),	  http://bits.blogs.nytimes.com/2014/07/23/open-­‐source-­‐and-­‐the-­‐challenge-­‐of-­‐making-­‐money/?_r=2.	  (“[h]aving	  many	  people	  in	  many	  places	  work-­‐ing	  on	  something.	  .	  .	  is	  a	  way	  to	  experiment	  with	  a	  lot	  of	  possibilities,	  make	  a	  lot	  of	  mistakes	  quick-­‐ly,	  figure	  out	  what	  works	  faster.”).	  	   128.	   Sigmond,	  supra	  note	  123,	  at	  90.	  
	   129.	   Id.	  	   130.	   Goldwater	  et	  al.,	  supra	  note	  121,	  at	  280	  ([o]pen	  source	  is	  defined	  as	  the	  “ability	  to	  copy,	  modify,	   use[,]	   and	   distribute	   software	   source	   code”	   and	   is	   thus	   freely	   available	   to	   all	   potential	  users).	  	   131.	   Sigmond,	  supra	  note	  123,	  at	  90.	  
	   132.	   Id.;	  Hardy,	   supra	   note	  127.	  Because	   everything	   is	   given	  away	   for	   free	   essentially,	   open	  source	  business	  models	  raise	   the	  “question	  of	  whether	   it	  makes	  sense	   to	  build	   free	  stuff	  at	  all.”	  Many	  who	  have	  used	  the	  open	  source	  strategy	  are	  not	  fond	  of	  it	  from	  a	  business	  perspective.	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  jects	  are	  often	  abandoned.133	   	  Finally,	  because	  open	  source	  software	  often	   is	  developed	   on	   a	   volunteer	   basis,	   there	   is	   no	   assurance	   that	   upgrades	   or	   bug	  fixes	  will	  be	  built	  at	  all.134	  The	  most	  popular	  success	  story	  of	  open	  source	  software	  is	  the	  Linux.	  	  At	  first,	   Linux	  was	  only	  a	  project	   that	  Linus	  Torvalds	  decided	   to	   create	   just	   for	  fun.135	   	  However,	  the	  software	  attracted	  the	  attention	  of	  other	  programmers,	  and	  programmers	  combined	  Linux	  with	  other	  open	  source	  software	  tools.136	  	  Soon	  enough,	  Linux	  become	  a	  serious	  operating	  system	  and	  has	  a	  license	  un-­‐der	  the	  General	  Public	  License	  (“GPL”).137	  	  The	  Linux	  Foundation	  now	  fosters	  open	   source	   collaborative	  projects	   throughout	   the	   software	   industry.	   	   Linux	  Foundation	  holds	  that	  people	  working	  together	  can	  use	  Linux	  to	  “solve	  harder	  problems,	   innovate	   faster	   than	   ever,	   and	   change	   the	   way	   the	   world	   works	  together.”138	  	  Essentially,	  Linus	  Torvaldus	  sparked	  an	  open	  source	  Revolution	  when	  he	  created	  Linux.139	  
B.	  Why	  Open	  Source	  for	  Synthetic	  Biology?	  An	  open	  source	  business	  model	  could	  benefit	  the	  field	  of	  synthetic	  bi-­‐ology	  as	  it	  has	  in	  the	  computer	  software	  industry.140	  	  Computer	  software	  and	  synthetic	   biology	   share	   many	   similarities	   that	   are	   readily	   apparent	   when	  comparing	   “strings	   of	   DNA	   bases”	   to	   software	   source	   code.141	   	   In	   the	   same	  way	   that	   programmers	   find	   bugs	   and	  write	   patches,	   biologists	   look	   for	   pro-­‐teins	   (“targets”)	   and	   select	   chemicals	   (“drug	   candidates”)	   that	   bind	   to	   them	  and	  affect	  their	  behavior	  in	  desirable	  ways.142	   	  Likewise,	  many	  argue	  that	  an	  open	  parts	  theory,	  which	  has	  benefited	  software	  in	  the	  past,	  would	  also	  help	  
	  	   133.	   Sigmond,	  supra	  note	  123,	  at	  90.	  
	   134.	   Id.;	  see	  also	  Goldwater	  et	  al.,	  supra	  note	  121,	  at	  280	  (in	  addition	  to	  the	  limited	  volunteers	  that	  may	  work	  on	  an	  open	  source	  project,	  only	  a	  small	  number	  of	   the	  suggested	  changes	  to	  the	  source	  code	  are	  even	  incorporated).	  	  
	   135.	   About	   Us,	   LINUX	   FOUNDATION,	   http://www.linuxfoundation.org/about	   (last	   visited	   Mar.	  24,	  2015).	  	  	   136.	   Sigmond,	   supra	   note	   123,	   at	   90;	   Goldwater	   et	   al.,	   supra	   note	   121,	   at	   280	   (although	   a	  “substantial	   number	   of	   developers	   refined	   and	   contributed	   changes	   to	   the	   source	   code,	   only	   a	  number	  of	  these	  suggested	  changes	  are	  incorporated	  into”	  the	  actual	  Linux	  software).	  	  
	   137.	   About	  us,	  supra	  note	  135.	  	  
	   138.	   Id.	  	  
	   139.	   Id.	  	  
	   140.	   See	  Ashlee	  Vance,	  Open	  Source	  as	  a	  Model	   for	  Business	  Is	  Elusive,	  N.Y.	  TIMES,	  (November	  29,	   2009),	   www.nytimes.com/2009/11/30/technology/business-­‐computing/30open.html?adxnnl=1&pagewanted=all&adxnnlx=1427209375-­‐WiT7B0umKeYH7c7meQhnzA.	  “The	  best-­‐known	  open-­‐source	  company	  is	  Red	  Hat,	  which	  produc-­‐es	  a	  variant	  of	  the	  Linux	  operating	  system	  for	  server	  computers.	  Like	  most	  of	  its	  peers,	  Red	  Hat	  offers	  a	  free	  version	  of	  its	  base	  product	  and	  relies	  on	  selling	  support	  services	  and	  extra	  tools	  for	  revenue.	  In	  its	  last	  fiscal	  year,	  which	  ended	  in	  March,	  the	  company’s	  revenue	  rose	  25	  percent	  to	  $653	  million,	  and	  it	  reported	  net	  income	  of	  $79	  million.”)	  	   141.	   Rai	  &	  Boyle,	  supra	  note	  2,	  at	  391.	  	   142.	   Maurer	  et	  al.,	  supra	  note	  117,	  at	  171.	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  advance	  research	  in	  synthetic	  biology.143	  In	   the	   software	   industry,	   complex	   computer	   chips	   and	   software	   are	  made	  up	  of	  multiple	  smaller	  parts.144	   	  Often,	  many	  of	   these	  parts	  come	  from	  open	  source	  libraries.145	  	  Similarly,	  biological	  systems	  are	  comprised	  of	  multi-­‐ple	  parts.146	  	  For	  example,	  Amyris	  Biotechnology	  synthesized	  yeast	  and	  bacte-­‐ria	  with	  multiple	  parts	  so	  that	  it	  could	  synthesize	  a	  drug	  called	  artemisinin.147	  	  Access	  to	  multiple	  parts	  would	  enable	  synthetic	  biologists	  to	  make	  biological	  systems—like	  complex	  software—more	  efficiently.148	  The	  idea	  for	  an	  open	  source	  business	  model	  for	  synthetic	  biology	  has	  been	  around	  since	  the	  emergence	  of	   the	   field.149	   	  Proponents	  of	  such	  a	  busi-­‐ness	  model	   “imagine	  a	  world	   in	  which	  academic	   researchers	  and	  companies	  who	  develop	  DNA	  parts	  share	  them	  freely	  with	  one	  [an]other	  to	  advance	  the	  whole	   field.”150	   	   Currently,	   however,	   “developers	   use	   patent	   protection	   and	  secrecy	   to	   hoard	   the	   best	   parts	   or	   otherwise	   charge	   others	   to	   use	   them.”151	  The	   key	   to	   a	   successful	   open	   source	   business	   model	   for	   synthetic	   biology	  would	  be	  to	  “create	  libraries	  of	  standard	  gene	  sequences	  (‘parts’)	  that	  reliably	  perform	  simple	  functions	  like	  encoding	  an	  enzyme	  or	  building	  a	  protein	  that	  detects	   light.”152	   	   Furthermore,	   these	   modular	   parts—which	   are	   termed	  “standards”—should	  be	  interchangeable	  with	  other	  systems.	  	  “Standards”	  are	  parts	   shared	   and	   known	   throughout	   a	   particular	   field	   of	   science	   to	   reliably	  perform	   the	   same	   function.153	   	   Because	   these	   standard	   parts	   “must	   be	   used	  together,”	   innovators	   share	   “a	   strong	   incentive	   to	   create	   entire	   libraries	   of	  parts,	   in	  much	  the	  same	  way	  that	  software	  companies	  develop	  multiple	  pro-­‐grams	   to	   cover	   a	   range	   of	   applications.”154	   	   Thus,	   proponents	   of	   an	   open	  source	  business	  model	  believe	  that	  implementation	  of	  the	  model	  will	  achieve	  this	  goal	  in	  the	  quickest	  way	  possible.155	  Furthermore,	   proponents	   of	   an	   open	   source	   business	  model	  want	   it	   to	  	  	   143.	   Maurer,	  supra	  note	  11,	  at	  806.	  	   144.	   Henkel	  &	  Maurer,	  supra	  note	  10,	  at	  1.	  
	   145.	   Id.	  
	   146.	   Id.;	  see	  also	  Torrence,	  supra	  note	  4,	  at	  39	  (like	  computer	  engineers,	  synthetic	  biologists	  also	  use	  multiple	  parts	  when	  working	  on	  a	  new	  product).	  	   147.	   Henkel	  &	  Maurer,	  supra	  note	  10,	  at	  1.	  
	   148.	   Id.	  	   149.	   Maurer,	  supra	  note	  11,	  at	  806.	  
	   150.	   Id.	  
	   151.	   Id.	  	  	   152.	   Henkel	  &	  Maurer,	  supra	  note	  10,	  at	  1;	  see	  also	  Ledford,	  supra	  note	  40,	  at	  16	   (synthetic	  biology’s	  success	  “hinges	  on	  the	  creation	  of	  standardized	  parts	  that	  can	  be	  combined	  in	  predicta-­‐ble	  ways”).	  
	   153.	   See	  Torrance	  &	  Kahl,	  supra	  note	  5,	  at	  206	  (noting	  that	  the	  types	  of	  standards	  that	  would	  be	  necessary	  include	  physical	  composition	  standards,	  functional	  composition	  standards,	  units	  of	  measurement	  standards,	  and	  data	  exchange	  standards).	  	   154.	   Henkel	  &	  Maurer,	  supra	  note	  10,	  at	  2.	  	  	   155.	   	  See	   generally	  Henkel	   &	   Maurer,	   supra	   note	   10,	   at	   2	   (noting	   that	   creating	   libraries	   of	  standards	  is	  key	  to	  an	  open	  source	  business	  strategy).	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  displace	   the	   current	   patent	   system	   because	   of	   the	   costs	   imposed	   by	   pa-­‐tents.156	  	  Proponents	  of	  an	  open	  source	  business	  models	  believe	  that	  the	  cur-­‐rent	   patent	   system	   inhibits	   innovation	   and	   that	   the	   open	   source	   business	  model	   can	   drive	   innovation.157	   	   One	   concern	   with	   the	   patent	   system	   is	   the	  broad	  reach	  of	   foundational	  patents	  and	  their	  ability	   to	   impede	  downstream	  research.158	  	  Another	  issue	  is	  the	  winner-­‐take-­‐all	  mentality	  of	  the	  patent	  sys-­‐tem.159	   	  The	   first	   innovator,	  or	  at	   least	   the	   first	   to	   the	  patent,	   is	  given	  a	  mo-­‐nopoly	  on	  his	  innovation.160	  	  In	  order	  to	  compete	  with	  companies	  that	  follow	  the	  current	  patent	  based	  business	  model	  of	  winner-­‐take-­‐all,	  synthetic	  biology	  companies	   could	   look	   towards	   an	   open	   source	   business	   model—like	   what	  Linux	  did	  to	  compete	  with	  Microsoft.161	  
C.	  Where	  is	  Open	  Source	  Currently	  Used	  in	  Science?	  Open	  source	  business	  models	  are	  starting	   to	  become	  relevant	   in	   the	  field	  of	   synthetic	  biology	   and	  biotechnology.	   	   For	   example,	   the	   International	  Genetically	  Engineered	  Machine	  (iGEM)	  Foundation	  has	  established	  the	  regis-­‐try	  of	  Standard	  Biological	  Parts.162	  	  iGEM	  allows	  others	  to	  use	  these	  parts	  but	  requires	  users	  to	  “contribute	  the	  parts	  they	  make	  to	  the	  Registry	  in	  the	  spirit	  of	   the	   ‘Get	  &	  Give’	   philosophy.”163	   	   Benefits	   of	   the	   registry	   include	   an	   easily	  accessible	  catalog	  of	  parts	  and	  devices,	  documentation	  and	  characterization	  of	  all	  parts	   that	  are	  user-­‐tested,	  a	   registry	   repository	   for	   samples,	   the	  BioBrick	  Standard,164	  and	  an	  open	  community	  where	  professionals	  share	   information	  and	  experiences.165	  Another	  proponent	  of	  an	  open	  source	  synthetic	  biology	  community	  is	  the	  BioBricks	  Foundation.	  	  BioBrick’s	  mission	  statement	  is	  to	  “ensure	  that	  the	  engineering	  of	  biology	  is	  conducted	  in	  an	  open	  and	  ethical	  manner	  to	  benefit	  all	  people	  and	  the	  planet.”166	  	  The	  purpose	  of	  the	  organization	  is	  to	  “launch	  an	  open-­‐source	   community”	   for	   synthetic	   biology.167	   	   BioBrick	   has	   created	   a	  	  	   156.	   Kumar	  &	  Rai,	  supra	  note	  28,	  at	  1747.	  
	   157.	   Id.;	  Hirsch	  &	  Hsu,	  supra	  note	  10	  (Elon	  Musk	  of	  Telsa	  Mortors	  Inc.,	  for	  example,	  believes	  that	  “patents	  are	  bad	  because	  they	  stifle	  innovation	  and	  creativity	  and	  encourage	  litigation”).	  	  	  
	   158.	   See	  supra	  Part	  III.B.	  	  	   159.	   Henkel	  &	  Maurer,	  supra	  note	  10,	  at	  1.	  
	   160.	   Id.	  at	  2.	  	  
	   161.	   Id.	  	  
	   162.	   Registry	  of	  Standard	  Biological	  Parts,	  IGEM,	  http://parts.igem.org/Main_Page	  (last	  visited	  Mar.	  24,	  2015).	  
	   163.	   Synthetic	  Biology	  based	  on	  Standard	  Parts,	  IGEM,	  http://igem.org/About	  (last	  visited	  Mar.	  24,	  2015)	  (iGEM	  was	  spun	  off	  from	  MIT).	  	   164.	   The	   BioBrick	   Standard	   “ensures	   compatibility	   between	   parts,	   allowing	   them	   to	   be	   as-­‐sembled	   together”	   with	   other	   parts	   into	   complex	   systems.	   Help:	   Philosophy,	   IGEM,	  http://parts.igem.org/Help:Philosophy	  (last	  visited	  Mar.	  24,	  2015).	  
	   165.	   Id.	  	  	  
	   166.	   About,	   BIOBRICKS	   FOUND.,	   http://biobricks.org/about-­‐foundation/	   (last	   visited	   Mar.	   24,	  2015).	  	   167.	   Fitzpatrick,	  supra	  note	  14,	  at	  1371–72.	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  “BioBrick	  Public	  Agreement	   (BPA)”	   that	   allows	   “individuals,	   companies,	   and	  institutions”	  to	  use	  parts	  and	  to	  “make	  their	  standardized	  biological	  parts	  free	  for	  others	  to	  use.”168	  	  The	  BPA	  contract	  requires	  the	  contributors	  to	  make	  an	  “irrevocable	  promise	  not	  to	  assert	  any	  existing	  or	  future	  intellectual	  property	  rights”	  over	  any	  part	  used	  by	  other	  parties	  to	  the	  contract—the	  users.169	  	  The	  users	   promise	   to	   “provide	   attribution	   to	   the	   Contributor,	   where	   requested,	  and	  to	  respect	  biological	  safety	  practices	  and	  applicable	  laws.”170	  Similarly,	  the	  International	  HapMap	  Project	  is	  another	  open	  source	  syn-­‐thetic	  biology	  community	  that	  maintains	  the	  “HapMap”	  catalog.171	  	  The	  “Hap-­‐Map”	  is	  a	  catalog	  of	  “common	  genetic	  variants	  that	  occur	  in	  human	  beings.”172	  	  The	  purpose	  of	   the	  project	   is	   to	   “provide	   information	   that	  other	  researchers	  can	  use	  to	  link	  genetic	  variants	  to	  the	  risk	  for	  specific	  illnesses,	  which	  will	  lead	  to	  new	  methods	  of	  preventing,	  diagnosing,	  and	  treating	  disease.”173	  Rather	   than	   sharing	   actual	   parts,	   the	   International	   HapMap	   Project	  shares	  “the	  genetic	  sequences	  of	  different	  individuals	  to	  identify	  chromosomal	  regions	  where	  genetic	  variants	  are	  shared”	  to	  help	  other	  biomedical	  research-­‐ers.174	  Another	  company	  that	  has	  created	  a	  parts	  library	  is	  Illumina,	  Inc.175	   	  Il-­‐lumina’s	  main	  source	  of	  business,	  however,	  is	  genomic	  sequencing	  and	  other	  genotyping	  services.176	  	  While	  Illumina	  utilizes	  patents	  for	  most	  of	  their	  prod-­‐ucts,	  they	  also	  have	  a	  data	  library	  freely	  available	  on	  their	  website.177	  	  Illumi-­‐na	  is	  unique	  as	  it	  asserts	  copyright	  protections	  on	  this	  data	  library.178	  Likewise,	  the	  medical	  field	  has	  utilized	  open	  source	  strategies	  as	  well.179	  	  Most	  initiatives	  in	  the	  medical	  field	  concern	  open	  source	  software	  rather	  than	  	  
	   168.	   The	  BioBrickTM	  Public	  Agreement	  (BPA),	  BIOBRICK	  FOUND.,	  https://biobricks.org/bpa/	  (last	  visited	  Mar.	  24,	  2015).	  
	   169.	   Frequently	  Asked	  Questions,	  supra	  note	  64.	  
	   170.	   Id.	  	  
	   171.	   What	   is	   the	   HapMap?,	   THE	   INTERNATIONAL	   HAPMAP	   PROJECT,	  	  http://hapmap.ncbi.nlm.nih.gov/whatishapmap.html.en	  (last	  visited	  Mar.	  24,	  2015).	  
	   172.	   Id.	  	  
	   173.	   Id.	  	  
	   174.	   About	   the	   HapMap,	   THE	   INTERNATIONAL	   HAPMAP	   PROJECT,	  http://hapmap.ncbi.nlm.nih.gov/thehapmap.html.en	  (last	  visited	  Sept.	  9,	  2014).	  
	   175.	   Data	   Library,	   ILLUMINA,	   http://science.illumina.com/science/data_library.ilmn	   (last	  visited	  Sept.	  9,	  2014).	  
	   176.	   Illumina	   Fact	   Sheet,	   ILLUMINA,	   http://www.illumina.com/company/about-­‐us/fact-­‐sheet.html	  (last	  visited	  Jan.	  21,	  2014).	  
	   177.	   Id.	  	  
	   178.	   See	  infra	  Part	  V.	  A.	  This	  Comment	  will	  discuss	  Illumina’s	  unique	  open	  parts	  strategy.	  	   179.	   Shawn	   N.	   Murphy	   et	   al.,	   Architecture	   of	   the	   Open-­‐source	   Clinical	   Research	   Chart	   from	  
Informatics	   for	   integrating	   Biology	   and	   the	   Bedside,	   AMIA	   ANNUAL	   SYMPOSIUM	   PROCEEDINGS	   548,	  548–52	  (2007),	  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2655844/	  (i2b2	  hive	  is	  an	  open	  source	   software	   platform	   for	   managing	   medical	   records	   and	   associated	   genomic	   data	   for	   re-­‐search.	   	   “One	  of	   the	   goals	   of	   i2b2	   is	   to	   provide	   clinical	   investigators	   broadly	  with	   the	   software	  tools	  necessary	  to	  collect	  and	  manage	  project-­‐related	  clinical	  research	  data	  in	  the	  genomics	  age	  as	  a	  cohesive	  entity,	  a	  software	  suite	  to	  construct	  and	  manage	  the	  modern	  clinical	  research	  chart.”).	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  actual	  medical	   research.180	   	  Open	   source	   initiatives	   in	   the	  medical	   field	   con-­‐tinue	  as	  well	  as	  open	  source	  initiatives	  in	  the	  biotechnology	  fields.	  Although	   many	   companies	   have	   begun	   open	   source	   initiatives	   or	  something	  similar,	  efforts	  for	  an	  open	  source	  community	  are	  only	  in	  the	  initial	  stages.181	   	   Researchers	  will	   need	   to	   collaborate	  with	   each	   other	   in	   order	   to	  create	   standard	   parts	   and	   a	   standard	   parts	   library.182	   	   Consequently,	   a	   re-­‐searcher	  can	  then	  mix	  and	  match	  parts	  from	  various	  libraries	  for	  a	  final	  prod-­‐uct	   at	   any	   part	   of	   the	   world.	   	   iGEM,	   for	   example,	   adheres	   to	   the	   BioBrick	  Standard,	  which	  seems	  to	  be	  the	  dominant	  standard	  in	  the	  industry.183	  	  Types	  of	  standards	  that	  would	  be	  necessary	  include	  physical	  composition	  standards,	  functional	  composition	  standards,	  units	  of	  measurement	  standards,	  and	  data	  exchange	  standards.184	  
D.	  Benefits	  of	  Open	  Source	  There	   are	   many	   benefits	   that	   open	   source	   business	   models	   would	  have	  for	  synthetic	  biology.	  	  First,	  the	  model	  allows	  companies	  the	  opportunity	  to	   share	   both	   their	   research	   and	   their	   development	   costs.185	   	   Consequently,	  other	  companies	  with	  access	  to	  that	  research	  would	  save	  on	  the	  costs	  for	  con-­‐ducting	   similar	   research.186	   	   Likewise,	   developmental	   costs	   for	   individual	  parts	  would	  decrease	  if	  parts	  are	  shared	  and	  reused.187	  	  Companies	  would	  be	  able	  to	  buy	  more	  parts	  rather	  than	  develop	  parts	  in	  house.	  
	  	   180.	   Hirsch	  &	  Hsu,	  supra	  note	  10.	  	  Tesla,	  for	  example,	  recently	  decided	  to	  open	  up	  its	  patents	  to	  “allow	  other	  manufacturers	  to	  use	  its	  patents	  in	  ‘good	  faith’	  —	  essentially	  barring	  those	  users	  from	   filing	   patent-­‐infringement	   lawsuits	   against	   the	   electric	   car	   company	   or	   trying	   to	   produce	  knockoffs	  of	  Tesla’s	  cars.”	  	   181.	   Maurer,	  supra	  note	  11,	  at	  806;	  see	  also	  A.	  L.	  Rector	  et	  al.,	  OpenGALEN:	  Open	  Source	  Medi-­‐
cal	   Terminology	   and	   Tools,	   AMIA	   ANNUAL	   SYMPOSIUM	   PROCEEDINGS	   982,	   982	   (2003),	  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1480228/.	  An	  open	  source	  project	   is	   the	  Open-­‐GALEN	  Foundation	  for	  a	  large	  ontology	  of	  the	  medical	  domain	  concerning	  human	  anatomy.	  “Cur-­‐rently	   available	   open	   source	   resources	   include	   a	   sophisticated	   ontology	   development	  environment	  and	  a	  large	  open	  source	  description	  logic-­‐based	  ontology	  for	  the	  medical	  domain.”	  	   182.	   A	  “standard”	  is	  basically	  a	  universally	  understood	  norm.	  Thus,	  if	  the	  industry	  followed	  a	  standard,	  everyone	  would	  be	  able	  to	  understand	  it.	  Torrance	  &	  Kahl,	  supra	  note	  5,	  at	  206–10.	  	  For	  example,	  the	  standard	  of	  good	  faith—it	  is	  universally	  understood	  to	  act	  in	  good	  faith.	  	  Id.	  	  Similar-­‐ly,	  it	  is	  important	  for	  parts	  to	  adhere	  to	  a	  Standard	  so	  that	  it	  may	  be	  used	  seamlessly	  and	  univer-­‐sally.	  	  Id.	  	   183.	   The	   BioBrick	   Standard	   “ensures	   compatibility	   between	   parts,	   allowing	   them	   to	   be	   as-­‐sembled	  together”	  with	  other	  parts	  into	  complex	  systems.	  See	  Help:	  Philosophy,	  supra	  note	  166.	  	  
	   184.	   See	  Torrance	  &	  Kahl,	  supra	  note	  5,	  at	  206;	  see	  also	  Henkel	  &	  Maurer,	  supra	  note	  10,	  at	  2	  (“[t]he	  fact	  that	  different	  parts	  must	  be	  used	  together	  also	  gives	  actors	  a	  strong	  incentive	  to	  create	  entire	   libraries	  of	   parts,	   in	  much	   the	   same	  way	   that	   software	   companies	  develop	  multiple	  pro-­‐grams	  to	  cover	  a	  range	  of	  applications.”).	  	   185.	   Maurer,	  supra	  note	  11,	  at	  807.	  
	   186.	   Id.	  	  	   187.	   Henkel	   &	  Maurer,	   supra	  note	   10,	   at	   1;	   Pearce,	   supra	  note	   76,	   at	   519	   (Costs	   would	   be	  further	  cut	  because	  most	  license	  fees	  would	  no	  longer	  be	  necessary.).	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  parts188	  would	  also	  be	  better	  than	  those	  developed	  in-­‐house.	  	  Presumably,	  all	  those	  who	  use	  the	  parts	  would	  be	  able	  to	  patch	  up	  any	  issues	  in	  the	  genetic	  code	  of	  the	  part	  used	  to	  ensure	  that	  the	  part	  can	  be	  used	  again.189	  	  Accordingly,	  the	  company	  that	  shared	  the	  part	  would	  expect	  others	  to	  find	  and	  improve	  the	  part—much	  like	  how	  open	  source	  software	  works.190	  	  As	  a	  result,	  shared	  parts	  will	  be	  more	  reliable.	  Third,	  with	  an	  open	  source	  business	  model,	   individual	  parts	  will	  be-­‐come	  relatively	  inexpensive.191	   	  Parts	  purchased	  repeatedly	  will	  become	  less	  expensive.192	   	  Once	  a	  company	  knows	  that	  a	  particular	  part	  is	  useful	  and	  the	  demand	   for	  said	  part	   is	  high,	   it	  will	  naturally	  work	  to	   increase	   the	  supply	  of	  the	  product.	   	  As	  a	   result,	   the	  company	  will	   figure	  out	  ways	   to	  mass-­‐produce	  the	   part,	   saving	   money	   on	   production	   costs,	   which	   would	   in	   turn	   decrease	  purchase	  pricing.	  Fourth,	   companies	   could	   produce	   new	   products,	   based	   on	   shared	  parts,	  at	  a	  faster	  rate.193	  	  If	  multiple	  parts	  are	  freely	  available,	  companies	  can	  produce	   larger	   and	   more	   useful	   products	   quicker.	   	   Furthermore,	   as	   more	  parts	  are	  utilized	  and	  patched,	  there	  will	  be	  fewer	  issues	  making	  sure	  differ-­‐ent	   parts	   are	   compatible	   in	   the	   same	   system—which	   is	   a	   common	   issue	   re-­‐searchers	   deal	   with	   when	   creating	   biological	   systems.194	   	   Access	   to	   large	  libraries	   of	   standard	   parts	   will	   allow	   researchers	   to	   think	   of	   final	   products	  rather	   than	   spending	   time	   creating	   the	   parts	   necessary	   for	   the	   final	   prod-­‐uct.195	   Fifth,	  costs	  would	  decrease	  in	  producing	  a	  final	  product.196	  	  Access	  to	  cheap	  and	  interchangeable	  parts	  will	  not	  only	  increase	  production	  time,	  it	  will	  also	  decrease	  costs	  for	  the	  final	  products.	   	  Likewise,	  transaction	  costs	  on	  pa-­‐	  	   188.	   See	  Torrance	  &	  Kahl,	  supra	  note	  5,	  at	  203	  (“[i]n	  theory,	  negative	  effects	  caused	  by	  patent	  rights	  covering	  commonly	  used	  components	  or	  methods	  in	  synthetic	  biology	  could	  be	  exacerbat-­‐ed	  if	  those	  patented	  components	  or	  methods	  were	  to	  be	  adopted	  as	  standards.”).	  	   189.	   Henkel	  &	  Maurer,	  supra	  note	  10,	  at	  1.	  	   190.	   Sigmond,	  supra	  note	  123,	  at	  90;	  John	  C.	  Newman	  &	  Robin	  Feldman,	  Copyright	  and	  Open	  
Access	   at	   the	   Bedside,	   365	   N.	   ENG.	   J.	   MED.	   2447,	   2449	   (2011),	  http://www.nejm.org/doi/full/10.1056/nejmp1110652.	   	   “Google,	  Apple,	   Facebook,	   and	  Twitter	  all	   use	   open-­‐source	   software	   at	   the	   heart	   of	   their	   products,	   because	   there	   is	   a	   clear	   economic	  benefit	  to	  using	  well-­‐tested,	  well-­‐validated,	  continually	  improved	  software	  in	  the	  core	  of	  complex	  products.	  	  Similarly,	  there	  is	  a	  clear	  clinical	  benefit	  to	  using	  well-­‐tested,	  well-­‐validated,	  continual-­‐ly	  improved	  clinical	  tools	  in	  complex	  patient	  care.”	  	   191.	   Henkel	  &	  Maurer,	  supra	  note	  10,	  at	  1.	  
	   192.	   Id.	  	  	   193.	   Maurer,	  supra	  note	  11,	  at	  807.	  	   194.	   Henkel	  &	  Maurer,	  supra	  note	  10,	  at	  1.	  	   195.	   T.Y.	  Leong	  et	  al.,	  Free	  and	  Open	  Source	  Enabling	  Technologies	   for	  Patient-­‐Centric,	  Guide-­‐
line-­‐Based	  Clinical	  Decision	  Support:	  a	  Survey,	  EUROPE	  PMC	  FUNDERS	  AUTHOR	  MANUSCRIPTS	  1	  (April	  23,	   2010),	   http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2858818/pdf/ukmss-­‐29401.pdf.	  “There	  are	  active	  and	  growing	  trends	  of	  deploying	  [Free	  Open	  Source]	  enabling	  technologies	  for	  integrating	  clinical	  guidelines,	  protocols,	  and	  pathways	  into	  the	  main	  care	  processes.	  	  The	  contin-­‐uing	  development	  and	  maturation	  of	  such	  technologies	  are	  likely	  to	  make	  increasingly	  significant	  contributions	  to	  patient-­‐centric,	  guideline-­‐based	  clinical	  decision	  support.”	  	  
	   196.	   Id.	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  tents	  would	  not	  be	  an	  issue.	  	  Thus,	  the	  developer	  would	  save	  on	  those	  transac-­‐tion	  costs	  as	  well.	  Sixth,	   “gaining	   reputation	   through	   publication	   is	   a	   particularly	  strong”	  incentive	  for	  biologists.197	  	  Likewise,	  biologists	  may	  have	  a	  number	  of	  other	   individualized	  motives	   including	   learning	  new	  skills,	  goodwill,	  and	   im-­‐pressing	  potential	  employers.198	  	  Although	  these	  motives	  may	  be	  limited,	  open	  source	  business	  models	  would	  not	  exist	  without	  them.199	  
E.	  Costs	  and	  Risks	  with	  Open	  Source	  Although	   benefits	   of	   an	   open	   source	   business	  model	   are	   numerous,	  there	  are	  also	  many	  risks	  and	  costs	  associated	  such	  business	  strategies.	  	  Some	  problems	  include	  “incentivizing	  entities	  to	  participate,	  maintaining	  openness	  once	  it	  is	  established,	  and	  creating	  useable	  biomedical	  products.”200	  First,	  incentives	  for	  implementing	  an	  open	  source	  business	  model	  are	  limited.201	   	   Some	   examples	   include	   individual	  motives	   of	   gaining	   reputation	  and	   impressing	   potential	   employers.202	   	   However,	   these	   incentives	   are	   not	  monetary	  incentives.	  	  By	  choosing	  an	  open	  source	  business	  model,	  an	  innova-­‐tor	  is	  essentially	  giving	  away	  his	  hard	  work	  to	  the	  world	  for	  free	  rather	  than	  attempting	  to	  commercialize	  the	  finding	  with	  a	  patent.203	  	  Accordingly,	  incen-­‐tives	  are	  limited.	  Second,	  companies	  that	  can	  afford	  patents	  tend	  to	  file	  for	  patents	  for	  many	  reasons.	   	  To	  begin,	  patents	  offer	  strong	  protection	  for	  innovations	  cre-­‐ated,	  whereas	   intellectual	  property	  out	   in	   the	  open	   is	  not	  protected.204	   	  Fur-­‐thermore,	  patents	  help	  increase	  a	  company’s	  economic	  value—which	  in	  turn	  attracts	  investors	  and	  business	  partners.205	  	  Patented	  genetic	  sequences	  “con-­‐stitute	  one	  of	  the	  most	  valuable	  assets	  owned	  by	  biotechnology	  companies.206	  	  Patents	   are	   exchangeable	   and	   valuable	   commodities	   that	   foster	   productivi-­‐ty.207	   	   Thus,	   companies	   that	   can	   afford	   patents	   have	   very	   little	   incentive	   to	  implement	  an	  open	  parts	  strategy.	  Third,	  companies	  that	  do	  implement	  an	  open	  source	  business	  model	  have	   limited	   protections	   for	   their	   work	   once	   they	   publish	   their	   findings.208	  	  	  	   197.	   Maurer	  et	  al.,	  supra	  note	  117,	  at	  171–72.	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   200.	   Fitzpatrick,	  supra	  note	  14,	  at	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   201.	   Maurer	  et	  al.,	  supra	  note	  117,	  at	  171–72.	  	   202.	   Maurer,	  supra	  note	  11,	  at	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   203.	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  35	  U.S.C.	  §	  102	  (2014).	  Public	   information	  cannot	  be	  patented	  (with	   limited	  excep-­‐tions).	  	  
	   204.	   Id.	  	   205.	   Torrance,	  supra	  note	  4,	  at	  15–16.	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   Id.	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   Id.	  at	  16.	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   Maurer	  et	  al.,	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476	   CHICAGO-­‐KENT	  JOURNAL	  OF	  INTELLECTUAL	  PROPERTY	   [Vol	  14:2	  Innovators	  fear	  that	  members	  of	  an	  open	  source	  project	  might	  divert	  “donated	  information	  into	  unauthorized	  commercial	  research.”209	  	  Accordingly,	  donors	  are	   hesitant	   to	   fund	   such	   projects	   that	   do	   not	   have	   guaranteed	   results.210	  	  Patents,	  however,	  provide	  a	  “way	  of	  sorting	  out	  the	  competing	  claims	  of	  par-­‐ticipants”	  and	  allow	  the	  original	  innovator	  complete	  rights	  to	  his	  findings.211	  Fourth,	  companies	  that	  do	  adopt	  an	  open	  source	  strategy	  often	  have	  trouble	   incentivizing	   other	   entities	   to	   participate	   in	   the	   project.212	   	   Just	   as	  donors	   are	   hesitant	   to	   donate	   funds	   to	   a	   project,	   individual	   companies	   are	  hesitant	  to	  participate.213	  	  Entities	  may	  similarly	  fear	  that	  their	  contributions	  will	   be	   improperly	   commercialized	   without	   receiving	   just	   compensation.214	  	  There	   is	  no	  guarantee	   that	  once	   information	   is	  shared	   that	  others	  will	   share	  their	  findings	  in	  return.215	  Fifth,	   innovation	  may	  be	  slower	   in	  an	  open	  parts	  business	  model.	   	   If	  everything	  is	  open	  source,	  then	  there	  is	  essentially	  no	  incentive	  to	  be	  the	  first	  innovate.	   	  While	   patents	   reward	   the	   first	   to	   innovate,	   open	   source	   business	  models	  have	  no	  comparable	   incentives.216	   	  Thus,	  creating	  useable	  parts,	  bio-­‐medical	   products	   may	   take	   longer	   than	   if	   there	   were	   proper	   incentives	   to	  work	  faster.	  Sixth,	   synthetic	   biology	   intellectual	   property	   has	   no	   forms	   of	   legal	  protection	  other	  than	  patents.217	   	  Accordingly,	  entities	  are	  reluctant	  to	  share	  their	  work.	  	  They	  fear	  that	  their	  hard	  work	  will	  be	  stolen,	  and	  they	  will	  not	  be	  adequately	   rewarded	   for	   their	   hard	   work.	   	   Thus,	   in	   order	   to	   donate	   infor-­‐mation,	   the	   donor	   essentially	   forfeits	   any	   intellectual	   property	   rights	   to	   the	  information.218	   	   Specifically,	   unlike	   software	   codes,	   coded	  genetic	   sequences	  do	  not	  have	  any	  copyright	  protections.219	  
F.	  Cost	  Benefit	  Analysis	  for	  Implementing	  an	  Open	  Source	  Business	  
Model	  When	  debating	  whether	  or	  not	   join	  an	  open	  source	  movement,	   syn-­‐thetic	  biologists	  must	  weigh	  and	  balance	  the	  different	  risks	  and	  benefits	  asso-­‐ciated	   with	   open	   source	   business	   models.	   	   As	   previously	   mentioned,	  companies	   that	   can	  afford	  patents	   are	   likely	   to	  obtain	  patents.	   	  However,	   as	  patents	   are	   expensive,	   open	   source	   strategies	   are	   more	   appealing	   to	   those	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  who	  cannot	  afford	  patents.	  	  Consequently,	  if	  a	  company	  decides	  to	  implement	  an	  open	  source	  business	  model,	   they	  cannot	  seek	   the	  protection	  of	  a	  patent.	  	  Companies	   that	   do	   implement	   an	   open	   source	   business	  model	   have	   limited	  protections	   for	   their	  work	   once	   they	  publish	   their	   findings.220	   	  Open	   source	  projects	  in	  the	  software	  industry	  utilize	  copyright	  protections,	  which	  are	  cur-­‐rently	  unavailable	  to	  genetic	  sequences.221	  	  Thus,	  synthetic	  biologists	  fear	  that	  shared	  information	  might	  be	  unfairly	  commercialized.222	  In	   addition	   to	   the	   lack	   of	   other	   intellectual	   property	  protections	   for	  genetic	  sequences,	   incentives	  for	  utilizing	  open	  source	  strategies	  are	   limited.	  	  Whether	  or	  not	  an	  innovator	  decides	  to	  utilize	  an	  open	  source	  strategy	  heavily	  depends	  on	   that	   innovator’s	  own	  personal	   incentives.223	   	   For	  example,	  most	  common	  incentives	  include	  increasing	  one’s	  reputation,	  a	  desire	  for	  goodwill,	  impressing	  potential	  employers,	  or	  learning	  and	  acquiring	  new	  skills.224	  	  If	  an	  individual	  does	  not	  have	  a	  personal	   incentive	  to	  share	   information,	  other	   in-­‐centives	  to	  join	  an	  open	  source	  project	  are	  limited.225	  	  This	  lack	  of	  other	  incen-­‐tives	   directly	   links	   to	   the	   fact	   that	   synthetic	   biology	   lacks	   other	   forms	  intellectual	  property	  protections.226	  Despite	   the	   lack	  of	  protections	  and	   incentives,	  open	  source	  business	  models	  are	  appealing	  to	  synthetic	  biologists.	  	  In	  theory,	  an	  open	  source	  strate-­‐gy	   allows	   innovators	   to	   share	   both	   their	   research	   and	   their	   development	  costs.227	  	  Were	  it	  not	  for	  the	  risks	  associated	  with	  open	  source	  business	  mod-­‐els,	  innovators	  would	  be	  more	  willing	  to	  join	  open	  source	  initiatives.	  	  Howev-­‐er,	   due	   to	   the	   lack	   of	   intellectual	   property	   protections	   for	   synthetic	   biology,	  open	  source	  projects	  have	  failed	  to	  gain	  widespread	  traction	  worldwide.	  V.	  POSSIBLE	  SOLUTIONS	  TO	  THE	  ISSUES	  WITH	  OPEN	  SOURCE	  Arguably,	  the	  greatest	  deterrent	  to	  an	  open	  source	  strategy	  is	  the	  lack	  of	  intellectual	   property	   protections	   for	   synthetic	   biology	   innovations.	   	   Other	  than	  patents,	  no	  other	  form	  of	  IP	  protection	  is	  available	  for	  genetic	  codes.	  	  For	  example,	   trademark	   protections	   are	   extremely	   limited	   in	   scope.	   	   Although	  trade	  secrets	  may	  be	  utilized	  to	  protect	  genetic	  information,	  this	  type	  of	  pro-­‐tection	  clashes	  with	  the	  concept	  of	  the	  open	  source	  strategy.	  	  If	  a	  company	  did	  try	   to	   utilize	   trade	   secrecy	  while	   sharing	   the	   physical	   parts	  without	   the	   se-­‐quences,	   other	   scientists	   could	   simply	   reverse-­‐engineer	   the	  part	   to	   discover	  the	  sequence.228	   	  Furthermore,	   if	  a	   third	  party	   independently	  discovered	  the	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  note	  5,	  at	  227.	  
	   222.	   See	  Maurer	  et	  al.,	  supra	  note	  117,	  at	  171.	  
	   223.	   Id.	  171–72.	  	   224.	   Maurer,	  supra	  note	  11,	  at	  807.	  	   225.	   Fitzpatrick,	  supra	  note	  14,	  at	  1364.	  	   226.	   Contributors	  fear	  that	  contributions	  will	  be	  improperly	  commercialized	  without	  receiv-­‐ing	  just	  compensation.	  See	  Maurer	  et	  al.,	  supra	  note	  117,	  at	  172	  	   227.	   Maurer,	  supra	  note	  11,	  at	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   228.	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  at	  808.	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  sequence	  or	  code	  supposedly	  protected	  as	  a	  trade	  secret,	  that	  proper-­‐ty	   right	   disappears.229	   	   Another	   “problem	  with	   trade	   secrets	   is	   that—unlike	  patents	   or	   copyright—a	   single	   unauthorized	   disclosure	   can	   destroy	   protec-­‐tion.”230	  	  Thus,	  trade	  secret	  protection	  is	  a	  risky	  and	  unreliable	  source	  of	  pro-­‐tection	  for	  synthetic	  biologists.	  The	  only	  protection	   that	  would	  make	  sense	   for	  genetic	  codes	  would	  be	   copyright	   protections.	   	   However,	   DNA	   sequences	   and	   genetic	   data	   is	   not	  copyright	   eligible.231	   	   The	   only	   existing	   type	   of	   protection	   for	   genetic	   data	  would	   be	   contractual—where	   parties	   would	   be	   contractually	   obligated	   to	  follow	  the	  rules	  of	  the	  open	  source	  project.232	  	  Part	  A	  first	  analyzes	  the	  bene-­‐fits	  of	   copyright	  protections	   for	  genetic	   sequences	   if	   extended	   to	   the	   field	  of	  synthetic	  biology.	   	  Parts	  B	  and	  C	  discuss	  licenses	  and	  contractual	  protections	  utilized	   in	   open	   source	   business	  models.	   	   Finally,	   Part	   D	   discusses	   how	   the	  government	   can	   help	   spur	   open	   source	  movements	   in	   the	   field	   of	   synthetic	  biology.	  
A.	  Copyrights	  If	  copyright	  law	  extended	  to	  the	  field	  of	  synthetic	  biology,	  it	  would	  be	  “relatively	  straightforward	  to	  implement	  open-­‐source	  synthetic	  biology	  in	  an	  analogous	   fashion	   to	   open-­‐source	   software.”233	   	   Copyright	   affords	   legal	   pro-­‐tection	  against	  unauthorized	  copying	   for	   “original	  works	  of	   authorship	   fixed	  in	   any	   tangible	   medium	   of	   expression,	   now	   known	   or	   later	   developed.”234	  	  Thus,	   if	  copyright	   law	  was	  to	  extend	  to	  synthetic	  biology,	   the	  actual	  codes—which	  are	  of	  value—could	  be	  protected.	  Unlike	  patent	   law,	   copyright	   law	   includes	   a	   provision	   that	   explicitly	  allows	  several	  significant	  uses	  of	  copyrighted	  works	  without	  resulting	   in	   lia-­‐bility	  for	  infringement”	  in	  §	  107	  of	  the	  Copyright	  act	  known	  as	  the	  “Fair	  Use”	  statute.235	   	   This	   statute	   allows	   copyrighted	   works	   to	   be	   used	   for	   purposes	  such	   as	   “criticism,	   comment,	   news	   reporting,	   teaching.	  .	  .,	   scholarship,	   or	   re-­‐search.”236	   	   This	   fair	   use	   defense	   creates	   a	   substantial	   “safe	   harbor	   within	  which	  socially	  valuable	  activities,	  such	  as	  academic	  research,	  may	  survive,	  and	  perhaps,	  even	  thrive.”237	  Furthermore,	   extending	   copyright	   protection	   to	   genetic	   sequences	  would	  allow	  for	  a	  much	  cheaper	  and	  quicker	  route	  to	  protection	  compared	  to	  
	  
	   229.	   	  Id.	  at	  809.	  
	   230.	   	  Id.	  	  	   231.	   Torrance	  &	  Kahl,	  supra	  note	  5,	  at	  227.	  	   232.	   Kumar	  &	  Rai,	  supra	  note	  28,	  at	  1765.	  	   233.	   Fitzpatrick,	  supra	  note	  14,	  at	  1378.	  	  	   234.	   17	  U.S.C.	  §	  102	  (2012).	  	   235.	   Torrance,	  supra	  note	  4,	  at	  38.	  	   236.	   17	  U.S.C.	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  107	  (2006).	  	  	   237.	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  supra	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  4,	  at	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  patent	  protection.238	   	  Likewise,	  the	  protection	  would	  last	  longer	  as	  copyright	  protections	   generally	   last	   for	   at	   least	   70	   years	   versus	   the	   20	   years	   of	   a	   pa-­‐tent.239	   	   Furthermore,	   unlike	   patents	   which	   provide	   for	   a	  monopoly	   on	   the	  sequence,	  fair	  use	  doctrines	  would	  allow	  others—especially	  those	  in	  academ-­‐ia—to	  use	  the	  information	  more	  freely.240	  	  This	  in	  and	  of	  itself	  would	  create	  an	  open	  source	  network	  for	  synthetic	  biologists.	  Although	  current	  copyright	  law	  does	  not	  extend	  to	  synthetic	  biology,	  Illumina,	  Inc.	  asserts	  copyright	  protection	  for	  some	  if	  its	  genetic	  sequences.241	  	  In	  addition	  to	  the	  legal	  terms	  on	  its	  website,	  Illumina	  asserts	  copyright	  protec-­‐tion	   for	   oligonucleotide	   primers	   compatible	   with	   its	   DNA	   sequencing	   ma-­‐chines	   as	   evidenced	   by	   a	   letter	   it	   had	   sent	   to	   customers.242	   	   It	   is	   unclear	  whether	  Illumina	  asserts	  this	  legal	  protection	  as	  a	  scare	  tactic	  or	  if	  they	  know	  something	  that	  is	  unknown	  to	  everyone	  else.	  Given	   the	   similarities	   between	   source	   code	   and	   genetic	   code,	  many	  scientists	  argue	  that	  copyright	  law	  should	  protect	  genetic	  sequences.243	  	  How-­‐ever,	  synthetic	  biology	  is	  not	  discussed	  as	  “copyrightable	  subject	  matter	  in	  the	  US	  copyright	  statute.”244	   	  Furthermore,	   “there	   is	  currently	  no	   indication	   that	  the	  U.S.	  Copyright	  Office	  or	  Congress	  would	  approve	  the	  use	  of	  Copyright	  Law	  to	   protect	   DNA	   sequences”245	   	   Accordingly,	   synthetic	   biologists	  will	   have	   to	  wait	  for	  the	  either	  the	  Courts	  or	  congress	  to	  address	  the	  applicability	  of	  copy-­‐right	  law	  to	  synthetic	  biology.	  
B.	  Licenses	  Because	  protection	  under	  copyright	  laws	  for	  genetic	  sequences	  is	  still	  unclear,	   a	   viable	   alternative—for	   protecting	   information	   for	   open	   source	  business	  models—is	  protection	  through	  licensing.	  	  Essentially,	  licenses	  would	  require	  entities—who	  wish	  to	  participate	  and	  use	  information	  shared	  in	  open	  source	   libraries—to	   sign	   a	   contract	   where	   they	   promise	   not	   to	   misuse	   the	  information	  shared.	  	  Licenses	  of	  this	  nature	  are	  copyleft	  licenses.246	  Copyleft	  licenses	  allow	  a	  user	  to	  utilize	  the	  code	  of	  a	  product	  but	  pro-­‐tect	  the	  new	  products	  or	  uses	  found	  for	  the	  code.247	  	  Copyleft	  Licenses	  require	  any	  user	  who	  uses	  the	  source	  code,	  modified	  or	  not,	  to	  “re-­‐license”	  the	  prod-­‐uct	   under	   “identical	   terms	   that	   allow	   any	   recipient	   to	   change	   the	   code”	   as	  	  	   238.	   Torrance	  &	  Kahl,	  supra	  note	  5,	  at	  227.	  	   239.	   17	  U.S.C.	  §	  302	  (2012).	  	   240.	   Torrance	  &	  Kahl,	  supra	  note	  5,	  at	  227.	  
	   241.	   Id.	  at	  n.153.	  
	   242.	   Id.	  	  
	   243.	   Id.	  at	  203.	  	   244.	   Rai	  &	  Boyle,	  supra	  note	  2,	  at	  391.	  	   245.	   Fitzpatrick,	  supra	  note	  14,	  at	  1384.	  	  	   246.	   Heather	  Meeker,	  Open	  Source	  and	  the	  Secrets	  of	  Commando	  Due	  Diligence,	  43	  TEX.	  J.	  BUS.	  L.	  561,	  562	  (2009).	  	  
	   247.	   Id.	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  well.248	   	   In	   this	   manner,	   entities	   do	   not	   need	   to	   worry	   about	   who	   misuses	  their	  products.	  Copyleft	   licenses	   are	   very	   common	   in	   open	   source	   software	   pro-­‐jects.249	   	  Not	  only	  do	   these	   licenses	  allow	   information	   to	  be	   freely	  available,	  but	  they	  “also	  require	  those	  who	  distribute	  improvements	  to	  the	  source	  code	  to	   make	   the	   improvements	   available	   on	   the	   same	   terms.”250	   	   Accordingly,	  these	  contracts	  would	  help	  ensure	  that	  the	  sequences	  shared	  are	  continually	  improved.	   	   In	   the	   software	   industry,	   these	   “licenses	   have	   produced	   well-­‐functioning	   code,”	   and	   prevented	   software	   from	   threats	   posed	   by	   copyright	  and	  patent—which	  would	  limit	  the	  free	  use	  of	  the	  software.251	  Although	   copyleft	   licenses	   have	   worked	   for	   the	   software	   industry,	  there	   is	  no	  guarantee	   that	   the	   same	  success	  will	   transfer	  over	   to	  genetic	   se-­‐quences.252	  	  For	  instance,	  copyleft	  licenses	  for	  software	  often	  utilize	  copyright	  law	   as	   another	   layer	   of	   protection	   to	   prevent	   individuals	   from	   copying	   and	  misusing	  information.	  	  As	  mentioned	  previously,	  this	  layer	  of	  protection	  is	  not	  necessarily	   available	   to	   synthetic	  biology.	   	   Furthermore,	  unlike	   the	   software	  industry,	  synthetic	  biology	  requires	  extensive	  and	  expensive	  clinical	  trials	  and	  testing	   to	   ensure	   that	   the	   codes	   are	   fully	   functional.253	   	   Patents	   have	   been	  traditionally	  used	  to	  protect	  R&D	  costs	  by	  allowing	  the	  holder	  to	  exclusively	  commercialize	   the	   product	   as	   a	   monopoly	   for	   a	   short	   period	   of	   time.254	   	   If	  licenses	  displace	  patents,	  there	  will	  be	  no	  legal	  monopoly	  for	  the	  developer	  to	  utilize.	   One	   particular	   copyleft	   license	   that	   open	   source	   movements	   in	   the	  software	   industry	   have	   utilized	   is	   the	   General	   Public	   License	   (GPL).255	   	   The	  GPL	   could	  easily	  be	   “adapted	   to	   cover	  DNA	  and	  would	  have	   the	   same	  open-­‐source	   effect.”256	   	   A	   modified	   GPL	   would	   allow	   genetic	   sequences	   or	   novel	  combinations	  of	  sequences	  to	  be	  protected	  but	  available	  to	  the	  public.257	  
C.	  Contracts	  If	  a	  company	  does	  not	  have	  a	   license	  to	  sublicense	  a	  patent	  or	  other	  work,	  general	  contracts	  might	  be	  an	  alternative	  to	  promote	  open	  source	  busi-­‐	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  license.	  The	  author	  retains	  the	  right	  to	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  ness.258	   	  Through	  a	  contract,	  parties	  to	  an	  open	  source	  project	  can	  predeter-­‐mine	   all	   parameters	   and	   aspects	   to	   the	   agreement	   to	   share	   and	   use	   infor-­‐mation.259	  	  This	  will	  also	  give	  both	  parties	  flexibility	  and	  will	  clearly	  define	  the	  obligations	  of	  both	  parties.260	  However,	  contractual	  protection	   is	  not	   the	  strongest	   form	  of	  protec-­‐tion	  nor	  is	  it	  the	  best	  route	  for	  open	  source	  projects.	  	  First,	  the	  contract	  would	  limit	  the	  scope	  of	  use	  of	  the	  sequences	  involved	  in	  the	  contract.261	  	  Second,	  a	  contract	   would	   only	   be	   binding	   on	   the	   parties	   involved	   in	   the	   actual	   con-­‐tract.262	  	  Thus,	  intermediaries	  in	  any	  testing	  processes	  would	  not	  be	  obligated	  to	   follow	   the	   actual	   contract—unless	   they	   signed	   a	   second	   contract,	   which	  would	   create	   an	   unworkable	   web	   of	   contracts.	   	   Third,	   the	   larger	   the	   open	  source	  project,	  the	  harder	  it	  will	  be	  to	  enforce	  the	  contract	  to	  each	  individual	  entity.263	  	  Enforcing	  a	  contract	  may	  even	  result	  in	  excessive	  lawsuits	  that	  can	  be	  both	  time	  consuming	  and	  expensive.	  	  Therefore,	  even	  though	  contracts	  can	  be	  extremely	  flexible,	  it	  may	  not	  be	  the	  best	  way	  to	  protect	  information	  in	  an	  open	  source	  business	  model.	  VI.	  HOW	  THE	  GOVERNMENT	  CAN	  ASSIST	  IN	  AN	  OPEN	  SOURCE	  APPROACH	  The	  lack	  of	  other	  forms	  of	  intellectual	  property	  protection	  for	  genetic	  sequences	  and	  data	  is	  one	  of	  the	  greatest	  deterrents	  to	  an	  open	  source	  move-­‐ment	   in	  the	  field	  of	  synthetic	  biology.	   	  However,	   this	  deterrent	  would	  not	  be	  an	   issue	   if	   Congress	   or	   the	   courts	   were	   to	   extend	   copyright	   law	   to	   protect	  synthetic	  genetic	  codes.	  	  As	  discussed	  previously	  and	  by	  many	  other	  scholars,	  an	  open	  source	  movement	  in	  the	  field	  of	  synthetic	  biology	  would	  greatly	  bene-­‐fit	  from	  additional	  intellectual	  property	  protection.	   	  If	  Congress	  or	  the	  courts	  were	   to	   allow	   genetic	   data	   to	   be	   copyrightable,	   then	   more	   users	   would	   be	  willing	   to	  share	   their	   findings	  with	  others	  knowing	  that	   the	  work	   is	  protect-­‐ed.264	  	  Thus,	  innovators	  who	  share	  information	  will	  not	  have	  live	  with	  the	  fear	  that	  others	  will	  unfairly	  commercialize	  their	  work.265	  There	  is	  a	  second	  way	  by	  which	  the	  government	  can	  help	  foster	  open	  source	  strategies	  in	  the	  field	  of	  synthetic	  biology—by	  providing	  incentives	  to	  share	   findings	  with	   other	   researchers	   in	   the	   field.	   	   The	   government	   already	  contributes	   significant	   amounts	   of	   funding	   for	   scientific	   research.266	   	  While	  providing	  funding	  for	  research	  projects,	   if	  the	  government	  were	  to	  add	  addi-­‐	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  tional	  funding	  incentives	  to	  share	  basic	  parts	  with	  the	  rest	  of	  the	  community,	  synthetic	  biology	  would	  see	  an	  immediate	  open	  parts	  community	  and	  innova-­‐tion	  would	  occur	  more	  rapidly.	  The	  government	   is	  already	   funding	   large	  projects.	   	  For	  example,	   the	  Department	   of	   Energy’s	   $350	   million	   “biofuels	   initiative	   has	   no	   open-­‐parts	  requirement”	  but	  can	  easily	  add	  an	  incentive	  to	  share	  information.267	  	  Howev-­‐er,	  not	  all	  of	  those	  funds	  are	  going	  to	  the	  same	  researcher.	  	  While	  the	  govern-­‐ment	  is	  already	  spending	  so	  much	  money	  funding	  projects	  for	  various	  entities,	  if	  those	  entities	  were	  to	  share	  their	  findings	  with	  others	  in	  the	  field,	  the	  gov-­‐ernment	  may	  be	  able	  to	  save	  money	  by	  funding	  less	  projects.	  	  The	  government	  already	   promotes	   open	   source	   against	   software	   monopolies,	   such	   as	   Mi-­‐crosoft,	   and	   should	   extend	   this	   practice	   to	   the	   field	   of	   synthetic	   biology.268	  	  Practitioners	  would	  be	  able	  to	  save	  time	  and	  resources	  by	  taking	  advantage	  of	  past	  findings	  by	  other	  scientists	  in	  the	  field.	  	  Accordingly,	  adding	  incentives	  to	  opt	  for	  an	  open	  source	  business	  strategy	  will	  both	  foster	  innovation	  and	  save	  the	  government	  money	  for	  funding	  projects.	  As	   discussed	   previously,	   foundational	   patents	   hinder	   innovation.269	  	  The	  USPTO	  must	  enforce	  stricter	  patent	  guidelines	  to	  help	   limit	   the	  scope	  of	  patents	  and	  prevent	  foundational	  patents.270	  	  Stricter	  guidelines	  would	  ensure	  that	  basic	  parts	  are	  not	  patented.	   	  As	  previously	  mentioned,	  the	  USPTO	  does	  not	  have	  strict	  guidelines	  for	  patents	  related	  to	  synthetic	  biology.271	  	  Defining	  these	  guidelines	  and	  thus	  limiting	  scopes	  of	  patents	  will	  allow	  an	  open	  source	  movement	  to	  take	  place.	  	  Avoiding	  patent	  thickets	  will	  help	  innovators	  create	  new	  products.	  Furthermore,	  the	  USPTO	  may	  consider	  limiting	  the	  term	  of	  the	  patent.	  	  If	  patents	  are	  only	  valid	  for	  10	  or	  15	  years	  rather	  than	  20,	  that	  extra	  time	  from	  which	   the	   patent	   is	   no	   longer	   valid	  will	   allow	  users	   to	   create	   new	  products	  faster.	   	   In	  other	  words,	   if	   a	  basic	  part	   is	   covered	   for	  5	  or	  10	   less	  years,	   that	  part	  can	  be	  used	  to	  create	  new	  products	  at	  a	  faster	  rate.	   	  However,	  most	  pa-­‐tent	  prosecutors	  and	   companies	  would	  not	  prefer	   to	  have	  patent	   terms	   lim-­‐ited.	   	   Patents	   are	   expensive—thus	   patent	   holders	   want	   to	   keep	   their	  monopoly	  for	  as	  long	  as	  possible.	  To	   continue,	   like	   the	   USPTO,	   either	   Congress	   or	   the	   Courts	   should	  help	   limit	   the	  scope	  of	  patents	   in	   the	   field	  of	  synthetic	  biology.	   	  Like	   in	  Alice	  
Corp.,	  the	  courts	  should	  restrict	  patents	  on	  genetic	  data	  and	  products	  to	  limit	  the	  patentability	  of	  abstract	  ideas	  in	  the	  field	  of	  synthetic	  biology.272	  	  This	  will	  help	  synthetic	  biologists	   in	   two	  ways.	   	  First,	   this	  will	  help	   limit	   foundational	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  patents.273	   	  Second,	  clear	  guidelines	  on	  what	   is	  or	   is	  not	  patentable	  will	  help	  innovators	  determine	  when	  to	  seek	  patents.274	  	  The	  past	  few	  years	  have	  seen	  “tremendous	   flux”	   in	   how	   courts	   interpret	   nonobviousness	   and	   patent-­‐eligibility	  concerning	  synthetic	  biology.275	  Considering	   the	   alternatives	   to	  patent	  protections	  discussed	  above,	   the	  most	  viable	  source	  of	  protection	  is	  copyright	  protection.	  	  As	  of	  now,	  the	  Courts	  are	   silent	  as	   to	  whether	  or	  not	  genetic	   sequences	  can	  be	  protected	  by	  copy-­‐rights.276	  	  If	  the	  Courts	  or	  Congress	  were	  to	  dictate	  that	  copyright	  protections	  could	   extend	   to	   genetic	   data,	   open	   source	   movements	   would	   quickly	   pros-­‐per.277	   	  Just	  like	  software	  is	  protected	  by	  copyright	  law	  and	  has	  enjoyed	  suc-­‐cess	   through	   open	   source	   business	   strategies,	   genetic	   data	   could	   similarly	  benefit	  from	  copyright	  protection.	  VII.	  CONCLUSION	  Open	   source	   is	   strongly	   favored	   by	   researchers	   and	   innovators,	   but	  practitioners	   are	   hesitant	   to	   make	   any	   moves.	   	   Proponents	   of	   open	   source	  business	  models	   believe	   that	   the	   flaws	   in	   the	   current	   patent	   system	   hinder	  advancements	  in	  the	  field	  of	  synthetic	  biology.278	  	  Some	  of	  the	  issues	  associat-­‐ed	  with	   the	   patent	   system	   include	  patent	   thickets	   and	   foundational	   patents.	  	  Likewise,	  uncertainty	  of	  what	  is	  patent	  eligible	  also	  contributes	  to	  the	  stifling	  of	   innovation.279	   	  Open	  source	  business	  models	  have	  many	  benefits	  but	  also	  have	  many	  risks.280	  	  For	  instance,	  benefits	  of	  open	  source	  strategies	  include—but	  are	  not	  limited	  to—shared	  costs	  for	  research	  and	  development,	  better	  and	  cheaper	  products,	  and	  quicker	   innovations.281	   	  However,	  risks	   include	  a	   lack	  of	   incentives,	   predominance	   of	   patents,	   and	   limited	   non-­‐patent	   intellectual	  property	  protections	  for	  genetic	  data.282	  The	  positives	  of	  an	  open	  source	  strategy	  for	  synthetic	  biology	  are	  ex-­‐tremely	  significant.	   	  Further	  innovations	  will	  allow	  for	  greater	  advancements	  in	   the	   fields	   of	   biotechnology,	   medicine,	   biofuels,	   and	   even	   agriculture.283	  	  Practitioners	  must	  join	  open	  source	  movements	  to	  maximize	  the	  movement’s	  value.	  	  The	  government	  can	  even	  help	  aid	  the	  open	  source	  movement	  by	  cre-­‐	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  ating	  incentives	  for	  researchers	  funded	  by	  the	  government.284	  	  However,	  there	  are	   still	   many	   risks	   associated	   with	   such	   strategies,	   namely	   a	   lack	   of	   non-­‐patent	   intellectual	   property	   protection.285	   	   Until	   the	   risks	   associated	   with	  open	  source	  strategies	  are	  limited,	  practitioners	  will	  continue	  to	  be	  hesitant	  to	  join	  open	  source	  projects.286	  	  Innovators	  fear	  that	  if	  they	  share	  and	  participate	  in	   an	   open	   source	   project,	   others	   might	   take	   advantage	   of	   shared	   infor-­‐mation.287	   	   Given	   the	   lack	   of	   intellectual	   property	   protections	   for	   genomic	  sequences	   and	   data,	   innovators	   are	   unwilling	   to	   risk	   sharing	   their	   research	  and	   findings	  with	   potential	   competitors.288	   	   Protection	   from	   copyright	   laws	  would	  help	  alleviate	  such	  fears	  as	  innovators	  will	  have	  a	  layer	  of	  legal	  protec-­‐tion	  when	  sharing	  information.289	  	  The	  software	  industry	  and	  companies	  such	  as	   Linux	   have	   thrived	   in	   open	   source	   systems	   because	   software	   and	   source	  code	  can	  be	  protected	  by	  copyrights.290	   	   Innovators	  believe	  that	  similar	  pro-­‐tections	   for	   genetic	   sequences	  would	   allow	   synthetic	   biology	   to	   thrive	   in	   an	  open	  source	  system.291	  In	  conclusion,	  open	  source	  business	  models	  would	  be	  extremely	  ben-­‐eficial	   to	   synthetic	   biologists.	   	   Even	   though	   there	   are	   open	   source	   projects	  currently	  underway,	  the	  projects	  are	  only	  in	  initial	  stages.292	   	   Innovators	  are	  arguably	   justified	   in	   being	   hesitant	   to	   join	   such	   movements.	   	   However,	   be-­‐cause	  the	  benefits	  of	  open	  source	  business	  models	  are	  significant,	  application	  of	   open	   source	  business	  models	   to	   synthetic	  biology	  will	   be	  of	  much	  debate	  for	  some	  time.	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